Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	microfilament motor activity	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B	9.41e-07	38	176	6	GO:0000146
GeneOntologyMolecularFunction	ATP-dependent activity	MYH4 MYH6 MYH10 BRIP1 SPAST MYH13 MYO1E MYO7B ZGRF1 ABCC5 RNF213 ABCC9 MSH2 UPF1 ABCA8 DNAH1 DNAH12 ATF7IP MACF1	2.18e-06	614	176	19	GO:0140657
GeneOntologyMolecularFunction	cytoskeletal motor activity	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B DNAH1 DNAH12	9.96e-06	118	176	8	GO:0003774
GeneOntologyMolecularFunction	arachidonate epoxygenase activity	CYP2A6 CYP2A13 CYP4A11 CYP4A22	5.40e-05	24	176	4	GO:0008392
GeneOntologyMolecularFunction	ADP binding	MYH10 MSH2 GLUD1 GLUD2 PKM	6.33e-05	48	176	5	GO:0043531
GeneOntologyMolecularFunction	oxidoreductase activity, acting on the CH-NH2 group of donors, NAD or NADP as acceptor	GLUD1 GLUD2	7.73e-05	2	176	2	GO:0016639
GeneOntologyMolecularFunction	glutamate dehydrogenase [NAD(P)+] activity	GLUD1 GLUD2	7.73e-05	2	176	2	GO:0004353
GeneOntologyMolecularFunction	glutamate dehydrogenase (NAD+) activity	GLUD1 GLUD2	7.73e-05	2	176	2	GO:0004352
GeneOntologyMolecularFunction	glutamate dehydrogenase (NADP+) activity	GLUD1 GLUD2	7.73e-05	2	176	2	GO:0004354
GeneOntologyMolecularFunction	medium-chain fatty acid omega-hydroxylase activity	CYP4A11 CYP4A22	7.73e-05	2	176	2	GO:0140981
GeneOntologyMolecularFunction	16-hydroxypalmitate dehydrogenase activity	CYP4A11 CYP4A22	7.73e-05	2	176	2	GO:0103002
GeneOntologyMolecularFunction	arachidonate monooxygenase activity	CYP2A6 CYP2A13 CYP4A11 CYP4A22	8.74e-05	27	176	4	GO:0008391
GeneOntologyMolecularFunction	ATP hydrolysis activity	MYH4 BRIP1 SPAST MYO1E ABCC5 RNF213 ABCC9 MSH2 UPF1 ABCA8 DNAH12 ATF7IP MACF1	1.52e-04	441	176	13	GO:0016887
GeneOntologyMolecularFunction	coumarin 7-hydroxylase activity	CYP2A6 CYP2A13	2.30e-04	3	176	2	GO:0008389
GeneOntologyMolecularFunction	aromatase activity	CYP2A6 CYP2A13 CYP4A11 CYP4A22	2.47e-04	35	176	4	GO:0070330
GeneOntologyMolecularFunction	cytoskeletal protein binding	MYH4 MYH6 MYH10 CTTNBP2 SPAST MYH13 MAP1A MYO1E NDE1 MYO7B SPTBN2 OPHN1 CRYAB PPP2R2A AP1G1 SCN5A MAST1 MACF1 ROCK1 TAOK1 DAAM1 CROCC	2.76e-04	1099	176	22	GO:0008092
GeneOntologyMolecularFunction	dipeptidase activity	NAALAD2 FOLH1 ADAM10	4.98e-04	18	176	3	GO:0016805
GeneOntologyMolecularFunction	ribonucleoside triphosphate phosphatase activity	RALB MYH4 BRIP1 SPAST MYO1E BMS1 ABCC5 RNF213 ABCC9 MSH2 UPF1 ABCA8 DNAH12 ATF7IP MACF1 GNA11 GNAQ	5.14e-04	775	176	17	GO:0017111
GeneOntologyMolecularFunction	tau protein binding	MAP1A PPP2R2A ROCK1 TAOK1	7.13e-04	46	176	4	GO:0048156
GeneOntologyMolecularFunction	alkylglycerophosphoethanolamine phosphodiesterase activity	GNA11 GNAQ	7.59e-04	5	176	2	GO:0047391
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	CYP2A6 CYP2A13 CYP4A11 CYP4A22	9.07e-04	49	176	4	GO:0016712
GeneOntologyMolecularFunction	actin filament binding	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B SPTBN2 MACF1	9.35e-04	227	176	8	GO:0051015
GeneOntologyMolecularFunction	actin binding	MYH4 MYH6 MYH10 MYH13 MAP1A MYO1E MYO7B SPTBN2 OPHN1 MACF1 DAAM1 CROCC	1.15e-03	479	176	12	GO:0003779
GeneOntologyMolecularFunction	pyrophosphatase activity	RALB MYH4 BRIP1 SPAST MYO1E BMS1 ABCC5 RNF213 ABCC9 MSH2 UPF1 ABCA8 DNAH12 ATF7IP MACF1 GNA11 GNAQ	1.23e-03	839	176	17	GO:0016462
GeneOntologyMolecularFunction	hydrolase activity, acting on acid anhydrides	RALB MYH4 BRIP1 SPAST MYO1E BMS1 ABCC5 RNF213 ABCC9 MSH2 UPF1 ABCA8 DNAH12 ATF7IP MACF1 GNA11 GNAQ	1.25e-03	840	176	17	GO:0016817
GeneOntologyMolecularFunction	hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides	RALB MYH4 BRIP1 SPAST MYO1E BMS1 ABCC5 RNF213 ABCC9 MSH2 UPF1 ABCA8 DNAH12 ATF7IP MACF1 GNA11 GNAQ	1.25e-03	840	176	17	GO:0016818
GeneOntologyMolecularFunction	leukotriene-B4 20-monooxygenase activity	CYP4A11 CYP4A22	1.58e-03	7	176	2	GO:0050051
GeneOntologyMolecularFunction	alkane 1-monooxygenase activity	CYP4A11 CYP4A22	1.58e-03	7	176	2	GO:0018685
GeneOntologyMolecularFunction	centromeric DNA binding	MSH2 ZW10	1.58e-03	7	176	2	GO:0019237
GeneOntologyMolecularFunction	L-leucine binding	GLUD1 GLUD2	1.58e-03	7	176	2	GO:0070728
GeneOntologyMolecularFunction	1-acylglycerophosphocholine O-acyltransferase activity	MBOAT2 TAFAZZIN	2.09e-03	8	176	2	GO:0047184
GeneOntologyCellularComponent	myosin complex	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B	1.05e-05	59	177	6	GO:0016459
GeneOntologyCellularComponent	actin cytoskeleton	MYH4 MYH6 MYH10 CTTNBP2 MYH13 MYO1E MYO7B SPTBN2 OPHN1 CRYAB DOCK5 ACTR1A GYS2 MACF1 DAAM1 CROCC	3.31e-05	576	177	16	GO:0015629
GeneOntologyCellularComponent	myosin filament	MYH4 MYH6 MYH10 MYH13	5.47e-05	25	177	4	GO:0032982
GeneOntologyCellularComponent	cell cortex	MYH10 CTTNBP2 MYO1E SPTBN2 TRIP10 DENND2B RYR1 ACTR1A GYS2 ARHGEF9 MACF1 SPINK5	8.00e-05	371	177	12	GO:0005938
GeneOntologyCellularComponent	myosin II complex	MYH4 MYH6 MYH10 MYH13	8.68e-05	28	177	4	GO:0016460
GeneOntologyCellularComponent	chromosomal region	SP100 NDE1 NBN MSH2 UPF1 H3-4 NLRP2 CENPP KDM4A ZW10 NSMCE1 KNL1	2.59e-04	421	177	12	GO:0098687
GeneOntologyCellularComponent	muscle myosin complex	MYH4 MYH6 MYH13	3.08e-04	16	177	3	GO:0005859
GeneOntologyCellularComponent	perinuclear region of cytoplasm	SPAST UACA CNTRL SPTBN2 ABCC5 UPF1 ADAM10 CERT1 TRIP10 RYR1 ITPR1 EPG5 SORT1 AP1G1 SCN5A TAOK1 DAAM1 DOCK6 SPINK5	3.73e-04	934	177	19	GO:0048471
GeneOntologyCellularComponent	meiotic spindle	RPS6KA2 CNTRL MAPK15	5.23e-04	19	177	3	GO:0072687
GeneOntologyCellularComponent	Mre11 complex	SP100 NBN	7.01e-04	5	177	2	GO:0030870
GeneOntologyCellularComponent	chromosome, telomeric region	SP100 NBN MSH2 UPF1 H3-4 NLRP2 NSMCE1	7.68e-04	176	177	7	GO:0000781
Domain	Myosin_head_motor_dom	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B	1.34e-06	38	175	6	IPR001609
Domain	MYOSIN_MOTOR	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B	1.34e-06	38	175	6	PS51456
Domain	Myosin_head	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B	1.34e-06	38	175	6	PF00063
Domain	MYSc	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B	1.34e-06	38	175	6	SM00242
Domain	IQ_motif_EF-hand-BS	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B PPEF2 SCN5A	2.04e-06	90	175	8	IPR000048
Domain	IQ	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B PPEF2 SCN5A	2.62e-06	93	175	8	PS50096
Domain	IQ	MYH4 MYH6 MYH10 MYH13 MYO1E MYO7B PPEF2	4.51e-06	71	175	7	PF00612
Domain	P-loop_NTPase	RALB MYH4 MYH6 MYH10 BRIP1 SPAST MYH13 MYO1E MYO7B ZGRF1 BMS1 ABCC5 RNF213 ABCC9 MSH2 UPF1 NLRP2 ABCA8 DNAH1 DNAH12 UCK2 GNA11 GNAQ	4.56e-06	848	175	23	IPR027417
Domain	Myosin_N	MYH4 MYH6 MYH10 MYH13	9.38e-06	15	175	4	PF02736
Domain	Myosin_N	MYH4 MYH6 MYH10 MYH13	9.38e-06	15	175	4	IPR004009
Domain	IQ	MYH4 MYH6 MYH10 MYH13 MYO7B PPEF2 SCN5A	1.09e-05	81	175	7	SM00015
Domain	Myosin_tail_1	MYH4 MYH6 MYH10 MYH13	2.06e-05	18	175	4	PF01576
Domain	Myosin_tail	MYH4 MYH6 MYH10 MYH13	2.06e-05	18	175	4	IPR002928
Domain	Myosin-like_IQ_dom	MYH4 MYH6 MYH10 MYH13	2.59e-05	19	175	4	IPR027401
Domain	-	MYH4 MYH6 MYH10 MYH13	2.59e-05	19	175	4	4.10.270.10
Domain	-	RALB BRIP1 SPAST MYO1E MYO7B ZGRF1 BMS1 ABCC5 RNF213 ABCC9 MSH2 UPF1 NLRP2 ABCA8 DNAH1 DNAH12 UCK2 GNA11 GNAQ	7.61e-05	746	175	19	3.40.50.300
Domain	F_BAR	TRIP10 FCHO1 SRGAP1 ARHGAP29	8.08e-05	25	175	4	IPR031160
Domain	F_BAR	TRIP10 FCHO1 SRGAP1 ARHGAP29	8.08e-05	25	175	4	PS51741
Domain	ELFV_dehydrog_N	GLUD1 GLUD2	8.73e-05	2	175	2	PF02812
Domain	Glu/Leu/Phe/Val_DH_C	GLUD1 GLUD2	8.73e-05	2	175	2	IPR006096
Domain	Glu/Leu/Phe/Val_DH_dimer_dom	GLUD1 GLUD2	8.73e-05	2	175	2	IPR006097
Domain	Glu/Leu/Phe/Val_DH	GLUD1 GLUD2	8.73e-05	2	175	2	IPR006095
Domain	ELFV_dehydrog	GLUD1 GLUD2	8.73e-05	2	175	2	PF00208
Domain	NAD_bind_Glu_DH	GLUD1 GLUD2	8.73e-05	2	175	2	IPR033922
Domain	GLFV_DEHYDROGENASE	GLUD1 GLUD2	8.73e-05	2	175	2	PS00074
Domain	ELFV_dehydrog	GLUD1 GLUD2	8.73e-05	2	175	2	SM00839
Domain	Glu/Leu/Phe/Val_DH_AS	GLUD1 GLUD2	8.73e-05	2	175	2	IPR033524
Domain	SH3	MYO1E MYO7B SH3GL3 TRIP10 DOCK5 SRGAP1 ARHGEF9 MACF1 ARHGEF4	2.06e-04	216	175	9	PS50002
Domain	SH3_domain	MYO1E MYO7B SH3GL3 TRIP10 DOCK5 SRGAP1 ARHGEF9 MACF1 ARHGEF4	2.36e-04	220	175	9	IPR001452
Domain	PDED_dom	PDE6D UNC119	2.60e-04	3	175	2	IPR008015
Domain	-	PDE6D UNC119	2.60e-04	3	175	2	2.70.50.40
Domain	GMP_PDE_delta	PDE6D UNC119	2.60e-04	3	175	2	PF05351
Domain	Cyt_P450_E_grp-I_CYP2A-like	CYP2A6 CYP2A13	5.17e-04	4	175	2	IPR008067
Domain	Gprotein_alpha_Q	GNA11 GNAQ	5.17e-04	4	175	2	IPR000654
Domain	Cyt_P450_E_grp-I	CYP2A6 CYP2A13 CYP4A11 CYP4A22	8.22e-04	45	175	4	IPR002401
Domain	HSR	SP100 SP140L	8.57e-04	5	175	2	PS51414
Domain	HSR	SP100 SP140L	8.57e-04	5	175	2	PF03172
Domain	HSR_dom	SP100 SP140L	8.57e-04	5	175	2	IPR004865
Domain	SH3_1	MYO1E SH3GL3 TRIP10 DOCK5 SRGAP1 ARHGEF9 ARHGEF4	9.11e-04	164	175	7	PF00018
Domain	SH3	MYO1E MYO7B SH3GL3 TRIP10 DOCK5 SRGAP1 ARHGEF9 ARHGEF4	1.00e-03	216	175	8	SM00326
Domain	FCH	TRIP10 FCHO1 SRGAP1	1.09e-03	22	175	3	PF00611
Domain	FCH	TRIP10 FCHO1 SRGAP1	1.09e-03	22	175	3	SM00055
Domain	FCH_dom	TRIP10 FCHO1 SRGAP1	1.25e-03	23	175	3	IPR001060
Domain	RIH_assoc-dom	RYR1 ITPR1	1.28e-03	6	175	2	IPR013662
Domain	Ins145_P3_rec	RYR1 ITPR1	1.28e-03	6	175	2	PF08709
Domain	RIH_assoc	RYR1 ITPR1	1.28e-03	6	175	2	PF08454
Domain	RIH_dom	RYR1 ITPR1	1.28e-03	6	175	2	IPR000699
Domain	Ins145_P3_rcpt	RYR1 ITPR1	1.28e-03	6	175	2	IPR014821
Domain	Ryanodine_recept-rel	RYR1 ITPR1	1.28e-03	6	175	2	IPR015925
Domain	-	RYR1 ITPR1	1.28e-03	6	175	2	1.25.10.30
Domain	RYDR_ITPR	RYR1 ITPR1	1.28e-03	6	175	2	PF01365
Domain	TFR_dimer	NAALAD2 FOLH1	1.28e-03	6	175	2	PF04253
Domain	-	NAALAD2 FOLH1	1.28e-03	6	175	2	1.20.930.40
Domain	ARM-type_fold	DNAJC13 RIPOR2 CUL9 NCBP1 APOB ITPR1 DOCK5 AP1G1 ANKAR DAAM1	1.39e-03	339	175	10	IPR016024
Domain	Cyt_P450_CS	CYP2A6 CYP2A13 CYP4A11 CYP4A22	1.52e-03	53	175	4	IPR017972
Domain	TFR-like_dimer_dom	NAALAD2 FOLH1	1.78e-03	7	175	2	IPR007365
Domain	Cullin_CS	CUL4B CUL9	1.78e-03	7	175	2	IPR016157
Domain	CYTOCHROME_P450	CYP2A6 CYP2A13 CYP4A11 CYP4A22	2.00e-03	57	175	4	PS00086
Domain	-	CYP2A6 CYP2A13 CYP4A11 CYP4A22	2.13e-03	58	175	4	1.10.630.10
Domain	p450	CYP2A6 CYP2A13 CYP4A11 CYP4A22	2.13e-03	58	175	4	PF00067
Domain	SAND_dom	SP100 SP140L	2.36e-03	8	175	2	IPR000770
Domain	Cullin_neddylation_domain	CUL4B CUL9	2.36e-03	8	175	2	IPR019559
Domain	Cullin_Nedd8	CUL4B CUL9	2.36e-03	8	175	2	PF10557
Domain	Cullin_Nedd8	CUL4B CUL9	2.36e-03	8	175	2	SM00884
Domain	SAND	SP100 SP140L	2.36e-03	8	175	2	PF01342
Domain	SAND	SP100 SP140L	2.36e-03	8	175	2	PS50864
Domain	SAND	SP100 SP140L	2.36e-03	8	175	2	SM00258
Domain	AAA	SPAST ABCC5 RNF213 ABCC9 ABCA8 DNAH12	2.38e-03	144	175	6	SM00382
Domain	AAA+_ATPase	SPAST ABCC5 RNF213 ABCC9 ABCA8 DNAH12	2.38e-03	144	175	6	IPR003593
Domain	Cyt_P450	CYP2A6 CYP2A13 CYP4A11 CYP4A22	2.41e-03	60	175	4	IPR001128
Domain	HMG_box_2	SP100 UBTF	3.01e-03	9	175	2	PF09011
Domain	Cullin_homology	CUL4B CUL9	3.01e-03	9	175	2	IPR016158
Domain	MIR	RYR1 ITPR1	3.74e-03	10	175	2	PF02815
Domain	MIR_motif	RYR1 ITPR1	3.74e-03	10	175	2	IPR016093
Domain	Cullin	CUL4B CUL9	3.74e-03	10	175	2	PF00888
Domain	MIR	RYR1 ITPR1	3.74e-03	10	175	2	PS50919
Domain	MIR	RYR1 ITPR1	3.74e-03	10	175	2	SM00472
Domain	CULLIN_2	CUL4B CUL9	3.74e-03	10	175	2	PS50069
Domain	Cullin_N	CUL4B CUL9	3.74e-03	10	175	2	IPR001373
Domain	CULLIN_1	CUL4B CUL9	3.74e-03	10	175	2	PS01256
Domain	DHR-1_domain	DOCK5 DOCK6	4.54e-03	11	175	2	IPR027007
Domain	DHR_2	DOCK5 DOCK6	4.54e-03	11	175	2	PS51651
Domain	DHR_1	DOCK5 DOCK6	4.54e-03	11	175	2	PS51650
Domain	DHR-2	DOCK5 DOCK6	4.54e-03	11	175	2	PF06920
Domain	DOCK	DOCK5 DOCK6	4.54e-03	11	175	2	IPR026791
Domain	DOCK_C	DOCK5 DOCK6	4.54e-03	11	175	2	IPR010703
Domain	DOCK-C2	DOCK5 DOCK6	4.54e-03	11	175	2	PF14429
Domain	DHR-2	DOCK5 DOCK6	4.54e-03	11	175	2	IPR027357
Domain	-	EPHB2 CUL9 F8 EPHA4	4.90e-03	73	175	4	2.60.120.260
Domain	-	SP100 SP140L	5.42e-03	12	175	2	3.10.390.10
Domain	Peptidase_M28	NAALAD2 FOLH1	5.42e-03	12	175	2	PF04389
Domain	Peptidase_M28	NAALAD2 FOLH1	5.42e-03	12	175	2	IPR007484
Domain	SAND_dom-like	SP100 SP140L	5.42e-03	12	175	2	IPR010919
Domain	Pkinase_C	RPS6KA2 MAST1 ROCK1	7.10e-03	42	175	3	PF00433
Domain	RECEPTOR_TYR_KIN_V_2	EPHB2 EPHA4	7.38e-03	14	175	2	PS00791
Domain	RECEPTOR_TYR_KIN_V_1	EPHB2 EPHA4	7.38e-03	14	175	2	PS00790
Domain	Dynein_heavy_chain_D4_dom	DNAH1 DNAH12	7.38e-03	14	175	2	IPR024317
Domain	VitD_rcpt	NR5A2 NR1D2	7.38e-03	14	175	2	IPR000324
Domain	Tyr_kinase_rcpt_V_CS	EPHB2 EPHA4	7.38e-03	14	175	2	IPR001426
Domain	Dynein_heavy_dom-2	DNAH1 DNAH12	7.38e-03	14	175	2	IPR013602
Pathway	REACTOME_SIGNALING_BY_RHO_GTPASES_MIRO_GTPASES_AND_RHOBTB3	MYH10 UACA NDE1 ARHGEF12 NIPSNAP2 TRIP10 LETM1 OPHN1 CENPP DOCK5 SRGAP1 ARHGEF9 ARHGAP29 ROCK1 TAOK1 ARHGEF4 DAAM1 ZW10 DOCK6 KNL1 CPSF7	1.17e-05	720	143	21	M41838
Pathway	REACTOME_FATTY_ACIDS	CYP2A6 CYP2A13 CYP4A11 CYP4A22	2.78e-05	18	143	4	MM14841
Pathway	REACTOME_RHO_GTPASE_CYCLE	UACA ARHGEF12 NIPSNAP2 TRIP10 LETM1 OPHN1 DOCK5 SRGAP1 ARHGEF9 ARHGAP29 ROCK1 ARHGEF4 DAAM1 DOCK6 CPSF7	5.24e-05	450	143	15	M27078
Pathway	KEGG_MEDICUS_REFERENCE_LPA_GNAQ_11_RHOA_SIGNALING_PATHWAY	ARHGEF12 GNA11 GNAQ	8.21e-05	9	143	3	M47732
Pathway	REACTOME_SIGNALING_BY_RHO_GTPASES_MIRO_GTPASES_AND_RHOBTB3	MYH10 NDE1 ARHGEF12 NIPSNAP2 TRIP10 LETM1 OPHN1 CENPP DOCK5 SRGAP1 ARHGEF9 ARHGAP29 ROCK1 TAOK1 DAAM1 ZW10 DOCK6 CPSF7	9.98e-05	649	143	18	MM15690
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_SPTBN2_TO_MGLUR1_TRPC3_SIGNALING_PATHWAY	SPTBN2 ITPR1 GNAQ	1.16e-04	10	143	3	M47661
Pathway	WP_MICROTUBULE_CYTOSKELETON_REGULATION	EPHB2 STAT3 ROCK1 TAOK1 GNAQ	1.21e-04	48	143	5	M39566
Pathway	KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION	CYP4A11 ARHGEF12 CYP4A22 ITPR1 ROCK1 GNA11 GNAQ	1.68e-04	115	143	7	M9387
Pathway	REACTOME_CDC42_GTPASE_CYCLE	ARHGEF12 OPHN1 SRGAP1 ARHGEF9 ARHGAP29 ARHGEF4 DAAM1 DOCK6	1.81e-04	155	143	8	M41808
Pathway	WP_CELLTYPE_DEPENDENT_SELECTIVITY_OF_CCK2R_SIGNALING	RYR1 ITPR1 GNAQ	2.71e-04	13	143	3	M39589
Pubmed	FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2.	CUL4B MYH10 DNAJC13 CAD NOP56 UACA MYO1E RNF213 RPL14 UPF1 ANKZF1 LUZP1 DIMT1 CEP78 SUGP2 AP1G1 UBTF SRGAP1 MACF1 TAOK1 SF3B5	5.17e-12	601	177	21	33658012
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	MYH6 MYH10 DNAJC13 CAD CTTNBP2 MAP1A MYO1E SPTBN2 ARHGEF12 NIPSNAP2 RPL14 UPF1 LETM1 LUZP1 OPHN1 CRYAB ACTR1A PPP2R2A SUGP2 AP1G1 GLUD1 GLUD2 PKM MAST1 MACF1 GNAQ ARHGEF4 CROCC CNOT1 CPSF7	4.45e-11	1431	177	30	37142655
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	MIX23 RALB CYP2A6 MYH4 MYH6 SP100 CYP2A13 MYH10 MYH13 NOP56 CNTRL SPTBN2 MAFA CCDC150 NIPSNAP2 ABCC5 NCBP1 APOB RPL14 H3-4 LETM1 LUZP1 TRNT1 CTR9 GLUD1 GLUD2 PKM MACF1 ARHGEF4 EPHA4	5.36e-11	1442	177	30	35575683
Pubmed	RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock.	ARHGEF12 ROCK1 GNA11 GNAQ	3.23e-09	5	177	4	25857352
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	MYH10 DNAJC13 CAD SPTBN2 BMS1 RNF213 NBN NCBP1 MSH2 PPEF2 LETM1 LUZP1 ITPR1 SORT1 PPP2R2A ZFYVE9 CTR9 FDFT1 UBTF ROCK1 CRYBG3 CNOT1 KNL1	4.49e-09	1049	177	23	27880917
Pubmed	The Hsp70-Hsp90 co-chaperone Hop/Stip1 shifts the proteostatic balance from folding towards degradation.	CUL4B MYH10 DNAJC13 CAD NOP56 NCBP1 MSH2 RPL14 UPF1 STAT3 ACTR1A SUGP2 AP1G1 CTR9 PKM ZW10 CNOT1 CPSF7	5.42e-09	638	177	18	33239621
Pubmed	Impaired plasma membrane localization of ubiquitin ligase complex underlies 3-M syndrome development.	DNAJC13 CAD NOP56 MAP1A SPTBN2 CUL9 APOB LUZP1 DNAH1 DOCK5 PPP2R2A DNAH12 DIMT1 NR5A2 MACF1 DOCK6	6.20e-09	496	177	16	31343991
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	MYH10 DNAJC13 UACA FOLH1 BICRA RPS6KA2 TMEM63C RNF213 CPT1A CERT1 DENND2B DNAH1 DOCK5 PPARGC1B PPP2R2A TRNT1 SUGP2 ANKAR ARHGEF9 ANKRD11 MAST1 MACF1 ARHGEF4 DAAM1 CROCC DOCK6 CNOT1	1.03e-08	1489	177	27	28611215
Pubmed	Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90/R2TP chaperones.	RALB MYH10 CDV3 CAD NOP56 MYO1E NIPSNAP2 NCBP1 MSH2 RPL14 UPF1 CPT1A ANKZF1 TRIP10 LETM1 STAT3 PPP2R2A DIMT1 AP1G1 CTR9 GLUD1 PKM MACF1 UCK2 SF3B5 SPINK5	1.53e-08	1415	177	26	28515276
Pubmed	A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.	MYH10 CAD NOP56 UACA MYO1E SPTBN2 VPS8 BMS1 RNF213 NCBP1 MSH2 RPL14 UPF1 ADAM10 LETM1 STAT3 ITPR1 SORT1 ACTR1A PPP2R2A DIMT1 FDFT1 UBTF PCMTD2 ZW10 CNOT1	2.18e-08	1440	177	26	30833792
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	MYH10 RIPOR2 KIAA0513 VPS8 ARHGEF12 CUL9 ZNF365 EPG5 SUGP2 ARHGEF9 MAST1 MACF1 ARHGEF4 CROCC	2.58e-08	407	177	14	12693553
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	MYH10 MYH13 NOP56 UACA MYO1E CDK12 PEG10 SPTBN2 BMS1 TASP1 NCBP1 APOB RPL14 UPF1 ANKZF1 STAT3 LUZP1 CEP78 SUGP2 PKM FADS2 TAOK1 CNOT1 SF3B5 CPSF7	3.46e-08	1371	177	25	36244648
Pubmed	Functional proteomics mapping of a human signaling pathway.	MYH10 EVC2 CDK12 RNPC3 PEG10 VPS8 DENND2B EPG5 ZFYVE9 AP1G1 CTR9 ATF7IP MACF1 ROCK1 DAAM1 KNL1	7.02e-08	591	177	16	15231748
Pubmed	LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy.	MYH4 MYH10 DNAJC13 CAD UACA BMS1 MSH2 DOCK5 DOCK6 CNOT1	9.67e-08	202	177	10	33005030
Pubmed	Defining the membrane proteome of NK cells.	DNAJC13 CAD NOP56 NDE1 CNTRL HTATIP2 RNF213 MSH2 RPL14 CPT1A ANKZF1 ADAM10 LUZP1 SLC4A2 ITPR1 DNAJC14 AP1G1 FADS2 DAAM1 ZW10 CNOT1 CPSF7	1.43e-07	1168	177	22	19946888
Pubmed	A novel role for the peptidyl-prolyl cis-trans isomerase Cyclophilin A in DNA-repair following replication fork stalling via the MRE11-RAD50-NBS1 complex.	SP100 BRIP1 MAP1A CDK12 BMS1 NBN MSH2 PPP2R2A SUGP2 AP1G1 MACF1 CRYBG3 KNL1 CPSF7	1.59e-07	472	177	14	38943005
Pubmed	Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis.	RALB MYH10 CAD NOP56 CNTRL NCBP1 RPL14 UPF1 CPT1A RYR1 EPG5 DNAH1 ACTR1A DUOX1 AP1G1 PKM MACF1 CNOT1	1.87e-07	807	177	18	30575818
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	CUL4B SP100 ERBB4 MAP1A UACA BICRA HTATIP2 CUL9 RNF213 NBN ABCA8 LUZP1 PPP2R2A DIMT1 SUGP2 SCN5A MACF1 UCK2 CRYBG3 NSMCE1 KNL1	2.85e-07	1116	177	21	31753913
Pubmed	LukS-PV inhibits hepatocellular carcinoma cells migration by downregulating HDAC6 expression.	CUL4B RALB MYH10 CAD UACA MYO1E SPTBN2 RPL14 UPF1 CPT1A ACTR1A PKM GNA11 GNAQ TDRD6	3.27e-07	580	177	15	35676659
Pubmed	Direct interaction between hnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice.	DNAJC13 CDK12 NBN MAGEE2 NCBP1 MSH2 UPF1 DOCK5 ACTR1A GSDME MACF1 TAOK1 CNOT1 KNL1 CPSF7	3.42e-07	582	177	15	20467437
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	CWF19L2 CAD MAP1A NDE1 ZGRF1 CUL9 NBN LUZP1 CTR9 ATF7IP MACF1 ROCK1 CRYBG3 KNL1 CPSF7	3.89e-07	588	177	15	38580884
Pubmed	The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis.	UTP6 DNAJC13 NOP56 CDK12 RNPC3 BMS1 NCBP1 MSH2 RPL14 UPF1 CENPP DIMT1 CEP78 SUGP2 UBTF MACF1 CNOT1	3.93e-07	759	177	17	35915203
Pubmed	Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.	UTP6 SP100 MYH10 CAD NOP56 UACA MYO1E SPTBN2 BMS1 NCBP1 MSH2 RPL14 UPF1 LUZP1 ACTR1A PPP2R2A DIMT1 UBTF SRGAP1 GLUD1 PKM CPSF7	4.94e-07	1257	177	22	36526897
Pubmed	Comprehensive interactome profiling of the human Hsp70 network highlights functional differentiation of J domains.	DNAJC13 CAD NOP56 UACA PEG10 COQ5 SPTBN2 BMS1 NBN RPL14 UPF1 LETM1 SLC4A2 ITPR1 DNAJC14 CTR9 FDFT1 UBTF GLUD1 ANKRD11 FADS2 MACF1 CRYBG3 DAAM1	6.11e-07	1487	177	24	33957083
Pubmed	MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons.	CWF19L2 MYH10 DNAJC13 CAD NOP56 MAP1A CDK12 RNPC3 SPTBN2 BMS1 NCBP1 RPL14 UPF1 SUGP2 PKM MACF1 DOCK6 CNOT1 SF3B5 CPSF7	7.37e-07	1082	177	20	38697112
Pubmed	Network organization of the huntingtin proteomic interactome in mammalian brain.	MYH6 MYH10 MAP1A RPS6KA2 NIPSNAP2 ABCC9 ITPR1 AP1G1 GLUD1 GLUD2 PKM ROCK1 GNA11 GNAQ TDRD6	7.71e-07	621	177	15	22794259
Pubmed	Establishment and analysis of a mouse model that regulates sex-related differences in liver drug metabolism.	CYP2A6 CYP2A13 CYP4A11 CYP4A22	8.47e-07	15	177	4	29968852
Pubmed	A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation.	CDV3 DNAJC13 NOP56 MAP1A UACA MYO1E RC3H1 NBN UPF1 LUZP1 CENPP PPP2R2A CEP78 SUGP2 MACF1 CNOT1	1.05e-06	724	177	16	36232890
Pubmed	Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.	UTP6 MYH10 CAD NOP56 BMS1 NCBP1 APOB MSH2 RPL14 UPF1 LETM1 ACTR1A PPP2R2A MAPK15 DIMT1 AP1G1 CTR9 UBTF GLUD1 PKM TDRD6 CNOT1 CPSF7	1.07e-06	1425	177	23	30948266
Pubmed	∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.	MYH4 MYH6 MYH10 CAD MYH13 CCDC80 NCBP1 RPL14 UPF1 ACTR1A PPP2R2A UBTF PKM DAAM1 ZW10	1.28e-06	647	177	15	26618866
Pubmed	An Acetate-Specific GPCR, FFAR2, Regulates Insulin Secretion.	ITPR1 GNA11 GNAQ	1.29e-06	5	177	3	26075576
Pubmed	Procontractile G protein-mediated signaling pathways antagonistically regulate smooth muscle differentiation in vascular remodeling.	ARHGEF12 GNA11 GNAQ	1.29e-06	5	177	3	23129751
Pubmed	Myogenic vasoconstriction requires G12/G13 and LARG to maintain local and systemic vascular resistance.	ARHGEF12 GNA11 GNAQ	1.29e-06	5	177	3	31549965
Pubmed	Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1.	CUL4B MYH10 NOP56 CDK12 NCBP1 MSH2 RPL14 UPF1 LETM1 STAT3 AP1G1 CTR9 ROCK1 ZW10 CPSF7	1.44e-06	653	177	15	33742100
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	CUL4B UTP6 MYH10 CAD SPTBN2 BMS1 CUL9 NCBP1 MSH2 RPL14 UPF1 SUGP2 UBTF MACF1 CNOT1	1.44e-06	653	177	15	22586326
Pubmed	Zinc Fingers and Homeoboxes 2 (Zhx2) Regulates Sexually Dimorphic Cyp Gene Expression in the Adult Mouse Liver.	CYP2A6 CYP2A13 CYP4A11 CYP4A22	1.47e-06	17	177	4	27197076
Pubmed	A high-throughput approach for measuring temporal changes in the interactome.	CUL4B SP100 CDV3 MYO1E PEG10 NCBP1 MSH2 RPL14 CERT1 TRIP10 STAT3 ACTR1A PPP2R2A TRNT1 DIMT1 AP1G1 CTR9 PKM MACF1 ROCK1 ZW10 CROCC CNOT1	1.52e-06	1455	177	23	22863883
Pubmed	Two-Dimensional Fractionation Method for Proteome-Wide Cross-Linking Mass Spectrometry Analysis.	CUL4B MIX23 SP100 MYH10 CDV3 MYH13 NOP56 ZGRF1 SPTBN2 NIPSNAP2 MSH2 RPL14 ACTR1A PPP2R2A MACF1 ROCK1 SF3B5	1.76e-06	847	177	17	35235311
Pubmed	Proteome-wide identification of HSP70/HSC70 chaperone clients in human cells.	EPHB2 MYH10 CDV3 DNAJC13 BMS1 RNF213 NCBP1 UPF1 TRIP10 CRYAB ACTR1A PPP2R2A AP1G1 FDFT1 GLUD1 PKM FADS2 ROCK1 GNA11 CNOT1 KNL1 CPSF7	1.96e-06	1367	177	22	32687490
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	MYH10 DNAJC13 CAD CTTNBP2 NOP56 UACA RPS6KA2 SPTBN2 ARHGEF12 UPF1 LETM1 LUZP1 ACTR1A ATF7IP MACF1 ROCK1 CNOT1 EPHA4	2.34e-06	963	177	18	28671696
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	CAD UACA PCNX3 NDE1 CDK12 BMS1 TASP1 ARHGEF12 NBN ANKZF1 LUZP1 GREB1L ACTR1A DIMT1 AP1G1 CTR9 ARHGEF9 ANKRD11 MACF1 GNA11 DAAM1 CROCC SF3B5	2.45e-06	1497	177	23	31527615
Pubmed	G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension.	ARHGEF12 GNA11 GNAQ	2.56e-06	6	177	3	18084302
Pubmed	Peroxisome proliferator-activated receptor-α accelerates α-chlorofatty acid catabolism.	CYP4A11 CPT1A CYP4A22	2.56e-06	6	177	3	28007964
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	SPAST MYO1E FOLH1 PEG10 SPTBN2 ABCC5 CUL9 NCBP1 ZNF365 STAT3 CRYAB DNAJC14 CTR9 GLUD1 PKM MAST1 MACF1 TAOK1 KDM4A PCMTD2 NR1D2	2.70e-06	1285	177	21	35914814
Pubmed	Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex.	ERBB4 MYH10 RNF213 UPF1 STAT3 AP1G1 FDFT1 PKM ROCK1 CNOT1	3.99e-06	304	177	10	32235678
Pubmed	Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism.	EPHB2 MYH10 CDV3 CAD BICRA RPL14 UPF1 CENPP DIMT1 DNAJC14 CTR9 FDFT1 UBTF EDEM2 NR5A2 ANKRD11 KDM4A CNOT1 TAFAZZIN NSMCE1 CPSF7	4.43e-06	1327	177	21	32694731
Pubmed	Cytosolic GDH1 degradation restricts protein synthesis to sustain tumor cell survival following amino acid deprivation.	RNF213 GLUD1 KDM4A	4.47e-06	7	177	3	34269483
Pubmed	Characterizing ZC3H18, a Multi-domain Protein at the Interface of RNA Production and Destruction Decisions.	MYH10 NOP56 CDK12 SPTBN2 BMS1 NIPSNAP2 NCBP1 RPL14 UPF1 DIMT1 SUGP2 CTR9 PKM SF3B5 NSMCE1	5.63e-06	731	177	15	29298432
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	ERBB4 MYH10 CAD SPAST MAP1A KIAA0513 BSDC1 NIPSNAP2 RPL14 ITPR1 SUGP2 GLUD1 GLUD2 PKM FADS2 MACF1 CRYBG3 DAAM1 CNOT1	6.23e-06	1139	177	19	36417873
Pubmed	Mapping the MOB proteins' proximity network reveals a unique interaction between human MOB3C and the RNase P complex.	CDV3 CAD PEG10 MSH2 RPL14 STAT3 ACTR1A PPP2R2A GLUD1 PKM DOCK6	7.03e-06	399	177	11	37536630
Pubmed	Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways.	MYH10 CAD MAP1A CDK12 CNTRL ABCA8 SORT1 CRYAB ANKAR GLUD1 GLUD2 PKM PCMTD2	7.12e-06	564	177	13	21565611
Pubmed	DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma.	BRIP1 BICRA NBN MSH2	7.54e-06	25	177	4	20150366
Pubmed	Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.	MYH10 DNAJC13 NOP56 PEG10 BMS1 NCBP1 RPL14 UPF1 CPT1A TRIP10 LUZP1 ACTR1A DIMT1 SUGP2 UBTF CPSF7	7.68e-06	847	177	16	35850772
Pubmed	TBK1 phosphorylation activates LIR-dependent degradation of the inflammation repressor TNIP1.	MYH10 CAD NOP56 UACA MYO1E SPTBN2 APOB RPL14 UPF1 H3-4 DENND2B LUZP1 ITPR1 ACTR1A DIMT1 UBTF PKM	7.90e-06	949	177	17	36574265
Pubmed	Cross-Linking Mass Spectrometry Uncovers Interactions Between High-Density Lipoproteins and the SARS-CoV-2 Spike Glycoprotein.	SERPINA3 MYH6 MYH10 SPTBN2 APOB SPINK5	7.92e-06	92	177	6	37343697
Pubmed	The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.	CUL4B CWF19L2 BRIP1 NOP56 CDK12 BICRA NBN H3-4 LUZP1 SUGP2 UBTF ATF7IP ANKRD11 SF3B5 NSMCE1 KNL1 CPSF7	8.45e-06	954	177	17	36373674
Pubmed	ISG15 Connects Autophagy and IFN-γ-Dependent Control of Toxoplasma gondii Infection in Human Cells.	MYH10 CAD UACA MYO1E RNF213 STAT3 LUZP1 UBTF PKM	1.04e-05	268	177	9	33024031
Pubmed	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	CAD NOP56 CDK12 RC3H1 NCBP1 RPL14 UPF1 ANKZF1 DIMT1 CEP78 SUGP2 GLUD1 CNOT1 KNL1	1.09e-05	678	177	14	30209976
Pubmed	Repression of rRNA transcription by PARIS contributes to Parkinson's disease.	CAD NOP56 MSH2 RPL14 H3-4 DIMT1 AP1G1 GLUD1 PKM	1.17e-05	272	177	9	25315684
Pubmed	mTORC1 activity regulates post-translational modifications of glycine decarboxylase to modulate glycine metabolism and tumorigenesis.	MYH10 CAD UACA RC3H1 SPTBN2 NCBP1 UPF1 LUZP1 SUGP2	1.24e-05	274	177	9	34244482
Pubmed	Retinaldehyde dehydrogenase 2 and Hoxc8 are required in the murine brachial spinal cord for the specification of Lim1+ motoneurons and the correct distribution of Islet1+ motoneurons.	EPHB2 GDNF EPHA4	1.51e-05	10	177	3	15753214
Pubmed	Caspr2 interacts with type 1 inositol 1,4,5-trisphosphate receptor in the developing cerebellum and regulates Purkinje cell morphology.	MYH10 MAP1A ITPR1	1.51e-05	10	177	3	32675284
Pubmed	KAP1 facilitates reinstatement of heterochromatin after DNA replication.	UTP6 CAD NOP56 MAP1A CDK12 MSH2 UPF1 TRIP10 ACTR1A DIMT1 SUGP2 AP1G1 PKM CNOT1	1.65e-05	704	177	14	29955894
Pubmed	BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.	CAD NOP56 ARHGEF12 ABCC5 RPL14 UPF1 LETM1 STAT3 PKM ARHGAP29 MACF1 ROCK1 CRYBG3 CNOT1	1.76e-05	708	177	14	39231216
Pubmed	Targeted and Interactome Proteomics Revealed the Role of PHD2 in Regulating BRD4 Proline Hydroxylation.	MYH10 CAD BMS1 MSH2 RPL14 UPF1 PPP2R2A UBTF PKM ROCK1 CPSF7	1.78e-05	441	177	11	31239290
Pubmed	Large-scale proteomics and phosphoproteomics of urinary exosomes.	CUL4B SERPINA3 DNAJC13 MXRA5 SPAST MYH13 UACA ARHGEF12 TRIP10 RYR1 CRYAB ACTR1A PKM TAOK1 GNA11 GNAQ CROCC	1.89e-05	1016	177	17	19056867
Pubmed	Dilated Cardiomyopathy Overview	MYH6 ABCC9 SCN5A TAFAZZIN	2.09e-05	32	177	4	20301486
Pubmed	Molecular Characterization of the Oncogene BTF3 and Its Targets in Colorectal Cancer.	MYH10 CAD NOP56 UACA MYO1E NIPSNAP2 RPL14 UPF1 H3-4 LUZP1 ACTR1A UBTF PKM	2.13e-05	626	177	13	33644029
Pubmed	Competitive binding of E3 ligases TRIM26 and WWP2 controls SOX2 in glioblastoma.	UTP6 DNAJC13 NOP56 MAP1A PCNX3 SPTBN2 RYR1 CRYAB ACTR1A DIMT1 UBTF FADS2 CNOT1 SPINK5	2.53e-05	732	177	14	34732716
Pubmed	N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective.	MYH10 CDV3 NOP56 MAP1A CDK12 NBN RPL14 UPF1 STAT3 SUGP2 UBTF ATF7IP GLUD1 PKM MACF1 KNL1	2.54e-05	934	177	16	33916271
Pubmed	Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension.	CYP4A11 CYP4A22	2.58e-05	2	177	2	15611369
Pubmed	The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.	GNA11 GNAQ	2.58e-05	2	177	2	28248732
Pubmed	Glutamate dehydrogenase is essential to sustain neuronal oxidative energy metabolism during stimulation.	GLUD1 GLUD2	2.58e-05	2	177	2	28621566
Pubmed	GluD1 knockout mice with a pure C57BL/6N background show impaired fear memory, social interaction, and enhanced depressive-like behavior.	GLUD1 GLUD2	2.58e-05	2	177	2	32078638
Pubmed	Suppressed hepatocyte proliferation via a ROS-HNE-P21 pathway is associated with nicotine- and cotinine-enhanced alcoholic fatty liver in mice.	CYP2A6 CYP2A13	2.58e-05	2	177	2	30876690
Pubmed	Molecular characterization of the murine Coh locus: an amino acid difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh.	CYP2A6 CYP2A13	2.58e-05	2	177	2	1302041
Pubmed	Effect of pyrazole, cobalt and phenobarbital on mouse liver cytochrome P-450 2a-4/5 (Cyp2a-4/5) expression.	CYP2A6 CYP2A13	2.58e-05	2	177	2	1520280
Pubmed	Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.	CYP2A6 CYP2A13	2.58e-05	2	177	2	23917075
Pubmed	Identification of the molecular dysfunction caused by glutamate dehydrogenase S445L mutation responsible for hyperinsulinism/hyperammonemia.	GLUD1 GLUD2	2.58e-05	2	177	2	28911206
Pubmed	Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region.	EPHB2 EPHA4	2.58e-05	2	177	2	11572780
Pubmed	Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism.	APOB SORT1	2.58e-05	2	177	2	22751103
Pubmed	Molecular genetic testing of uveal melanoma from routinely processed and stained cytology specimens.	GNA11 GNAQ	2.58e-05	2	177	2	21945171
Pubmed	PKM2 promotes cell metastasis and inhibits autophagy via the JAK/STAT3 pathway in hepatocellular carcinoma.	STAT3 PKM	2.58e-05	2	177	2	33512635
Pubmed	Androgen-sensitive hypertension associates with upregulated vascular CYP4A12-20-HETE synthase.	CYP4A11 CYP4A22	2.58e-05	2	177	2	23641057
Pubmed	Nuclear accumulation of pyruvate kinase M2 promotes liver regeneration via activation of signal transducer and activator of transcription 3.	STAT3 PKM	2.58e-05	2	177	2	32198052
Pubmed	Molecular basis of human glutamate dehydrogenase regulation under changing energy demands.	GLUD1 GLUD2	2.58e-05	2	177	2	15578726
Pubmed	Induction of excitatory and inhibitory presynaptic differentiation by GluD1.	GLUD1 GLUD2	2.58e-05	2	177	2	22138648
Pubmed	Altered inflammatory responses to Citrobacter rodentium infection, but not bacterial lipopolysaccharide, in mice lacking the Cyp4a10 or Cyp4a14 genes.	CYP4A11 CYP4A22	2.58e-05	2	177	2	24413902
Pubmed	PKM2 aggravates palmitate-induced insulin resistance in HepG2 cells via STAT3 pathway.	STAT3 PKM	2.58e-05	2	177	2	28802581
Pubmed	Circadian Regulation of Hepatic Cytochrome P450 2a5 by Peroxisome Proliferator-Activated Receptor γ.	CYP2A6 CYP2A13	2.58e-05	2	177	2	30154104
Pubmed	The Complex Effects of PKM2 and PKM2:IP3R Disruption on Intracellular Ca2+ Handling and Cellular Functions.	ITPR1 PKM	2.58e-05	2	177	2	37947604
Pubmed	Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo.	CYP2A6 CYP2A13	2.58e-05	2	177	2	21418183
Pubmed	Gonadotropin and gonadal steroid release in response to a gonadotropin-releasing hormone agonist in Gqalpha and G11alpha knockout mice.	GNA11 GNAQ	2.58e-05	2	177	2	9607776
Pubmed	Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors.	GNA11 GNAQ	2.58e-05	2	177	2	26628681
Pubmed	Potentiation of neuronal activity by tonic GluD1 current in brain slices.	GLUD1 GLUD2	2.58e-05	2	177	2	37154294
Pubmed	The time-course of agonist-induced solubilization of trimeric G(q)alpha/G(11)alpha proteins resolved by two-dimensional electrophoresis.	GNA11 GNAQ	2.58e-05	2	177	2	17552882
Pubmed	Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension.	CYP4A11 CYP4A22	2.58e-05	2	177	2	11320253
Pubmed	Transcriptional regulator CTR9 promotes hepatocellular carcinoma progression and metastasis via increasing PEG10 transcriptional activity.	PEG10 CTR9	2.58e-05	2	177	2	34876700
Pubmed	Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.	GNA11 GNAQ	2.58e-05	2	177	2	29209985
Pubmed	Characterization of the CYP4A11 gene, a second CYP4A gene in humans.	CYP4A11 CYP4A22	2.58e-05	2	177	2	12464262
Interaction	LRRC31 interactions	MYH4 MYH10 DNAJC13 CAD UACA BMS1 MSH2 TRIP10 DOCK5 DOCK6 CNOT1	1.85e-06	205	175	11	int:LRRC31
Interaction	HDAC6 interactions	CUL4B RALB ERBB4 MYH10 RIPOR2 CAD BRIP1 UACA MYO1E SPTBN2 HTATIP2 NBN MSH2 RPL14 UPF1 CPT1A STAT3 DOCK5 ACTR1A PKM GNA11 GNAQ TDRD6	5.91e-06	929	175	23	int:HDAC6
Interaction	KCTD13 interactions	MYH6 MYH10 DNAJC13 CAD CTTNBP2 MAP1A MYO1E SPTBN2 ARHGEF12 NIPSNAP2 RPL14 UPF1 LETM1 LUZP1 OPHN1 CRYAB ACTR1A PPP2R2A SUGP2 AP1G1 GLUD1 PKM MAST1 MACF1 GNAQ ARHGEF4 CROCC CNOT1 CPSF7	9.77e-06	1394	175	29	int:KCTD13
Interaction	HECTD1 interactions	EPHB2 UTP6 MYH10 DNAJC13 NOP56 CDK12 RNPC3 BMS1 NCBP1 MSH2 RPL14 UPF1 STAT3 CENPP DIMT1 CEP78 SUGP2 RASSF6 UBTF ANKRD11 MACF1 IGSF1 CNOT1	1.49e-05	984	175	23	int:HECTD1
Interaction	USP48 interactions	CUL4B MYH10 UACA HTATIP2 NIPSNAP2 RNF213 UPF1 FCHO1 SLC4A2 CRYAB UNC119 ACTR1A GSDME GLUD1 PKM CROCC NR1D2 CPSF7	2.18e-05	668	175	18	int:USP48
Interaction	CDC42 interactions	MYH10 PDE6D MYO1E PCNX3 SPTBN2 ARHGEF12 ABCC5 MSH2 CPT1A TRIP10 OPHN1 SLC4A2 ITPR1 UNC119 PPP2R2A SRGAP1 GLUD2 ARHGEF9 ARHGAP29 UCK2 ROCK1 TAOK1 GNA11 ARHGEF4 DAAM1 ZW10 CNOT1	2.89e-05	1323	175	27	int:CDC42
GeneFamily	Myosin heavy chains	MYH4 MYH6 MYH10 MYH13	1.94e-06	15	114	4	1098
GeneFamily	Rho GTPase activating proteins\|F-BAR domain containing	TRIP10 FCHO1 SRGAP1	3.94e-04	23	114	3	1288
GeneFamily	Cullins	CUL4B CUL9	1.08e-03	8	114	2	1032
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	EPHB2 SP100 DNAJC13 SPAST RPS6KA2 NBN MSH2 ADAM10 MBOAT2 DENND2B ITPR1 PPP2R2A ZFYVE9 ARHGAP29 MACF1 UCK2 ROCK1 GNAQ CRYBG3 DAAM1 EPHA4	3.67e-07	856	177	21	M4500
Coexpression	AIZARANI_LIVER_C9_LSECS_1	CUL4B MYH10 UACA BSDC1 F8 LUZP1 NR5A2 ANKRD11 ARHGAP29 MACF1 DAAM1	7.56e-06	304	177	11	M39113
Coexpression	PUJANA_ATM_PCC_NETWORK	SP100 CDV3 DNAJC13 RIPOR2 CAD PDE6D SPAST NOP56 CNTRL BMS1 CUL9 NBN NCBP1 MSH2 RPL14 CPT1A ADAM10 FCHO1 DIMT1 CTR9 PKM ROCK1 KDM4A GNAQ CNOT1	7.99e-06	1394	177	25	M9585
Coexpression	LAKE_ADULT_KIDNEY_C2_PODOCYTES	CTTNBP2 UACA MYO1E ARHGEF12 DOCK5 SRGAP1 ANKRD11 MACF1 ROCK1	1.48e-05	212	177	9	M39221
Coexpression	AIZARANI_LIVER_C20_LSECS_3	CUL4B UACA F8 LUZP1 SRGAP1 NR5A2 ANKRD11 ARHGAP29 MACF1 DAAM1	3.45e-05	295	177	10	M39121
Coexpression	GSE6259_33D1_POS_DC_VS_CD4_TCELL_UP	CDV3 MNS1 MSH2 ITPR1 DOCK5 ARHGEF9 FADS2 KNL1	3.76e-05	184	177	8	M6756
Coexpression	GSE17721_LPS_VS_POLYIC_1H_BMDC_DN	MNS1 BMS1 CERT1 LUZP1 OPHN1 SORT1 UBTF TAOK1	6.53e-05	199	177	8	M3800
Coexpression	GSE21379_WT_VS_SAP_KO_TFH_CD4_TCELL_UP	CELF5 RALB EVC2 MYO1E OPHN1 DOCK5 ARHGAP29 DOCK6	6.77e-05	200	177	8	M7501
Coexpression	GSE9509_LPS_VS_LPS_AND_IL10_STIM_IL10_KO_MACROPHAGE_10MIN_DN	PDE6D NDE1 COQ5 MSH2 SLC4A2 FDFT1 ATF7IP TAFAZZIN	6.77e-05	200	177	8	M6896
Coexpression	GSE3203_HEALTHY_VS_INFLUENZA_INFECTED_LN_BCELL_UP	CYP2A6 MYH6 DNAJC13 MNS1 F8 LETM1 STAT3 NSMCE1	6.77e-05	200	177	8	M6785
ToppCell	mild-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CWF19L2 SP100 RNPC3 RNF213 CEP78 SUGP2 ATF7IP ANKRD11 MACF1	1.09e-07	199	177	9	f0b0097df0026496470a80d8cc9375ffd8389b00
ToppCell	Macroglial-Oligodendrocytes\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MYO1E FOLH1 SH3GL3 FCHO1 ABCA8 SORT1 GREB1L CRYAB DOCK5	1.14e-07	200	177	9	4dbac2f2587e87ca5a0622f50439bb5447e93c7f
ToppCell	Macroglial-Oligodendrocytes-OPALIN--\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MYO1E FOLH1 SH3GL3 FCHO1 ABCA8 SORT1 GREB1L CRYAB DOCK5	1.14e-07	200	177	9	26b989e30bbbaf30904ced03f6aae3dea25c732c
ToppCell	Macroglial-Oligodendrocytes-OPALIN---\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MYO1E FOLH1 SH3GL3 FCHO1 ABCA8 SORT1 GREB1L CRYAB DOCK5	1.14e-07	200	177	9	1314664c1721e9ecb1e2c3482a039044b0fe50a9
ToppCell	Macroglial-Oligodendrocytes-OPALIN-\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MYO1E FOLH1 SH3GL3 FCHO1 ABCA8 SORT1 GREB1L CRYAB DOCK5	1.14e-07	200	177	9	8b229f095fc113aecfc94b64862a9e0fdcc363ce
ToppCell	Macroglial-Oligodendrocytes-OPALIN----L1-6\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MYO1E FOLH1 SH3GL3 FCHO1 ABCA8 SORT1 GREB1L CRYAB DOCK5	1.14e-07	200	177	9	272909f4354f3ae22e2b2f8f35970e6b0e92cfe2
ToppCell	Macroglial-Oligodendrocytes-OPALIN\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MYO1E FOLH1 SH3GL3 FCHO1 ABCA8 SORT1 GREB1L CRYAB DOCK5	1.14e-07	200	177	9	5f75a9b8bcd49d9bbb1e9ce2de730eaec96369ca
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	RNF213 ITPR1 EPG5 AP1G1 ATF7IP ANKRD11 MACF1 TAOK1	8.92e-07	188	177	8	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	LA-13._Vascular_Smooth_Muscle\|LA / Chamber and Cluster_Paper	ERBB4 MYH10 MYO1E TASP1 ITPR1 SORT1 MACF1 ROCK1	8.92e-07	188	177	8	34e1b074a3995aa46ab194eb45115d76d1a5514d
ToppCell	LPS_IL1RA-Endothelial-Endothelial\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	UACA RPS6KA2 ARHGEF12 RNF213 LUZP1 ARHGAP29 MACF1 DOCK6	1.42e-06	200	177	8	72ea9882a8ed26fa1534aeb6ba0d1897dccc20c5
ToppCell	LPS_IL1RA\|World / Treatment groups by lineage, cell group, cell type	CDV3 MYO1E ARHGEF12 NBN SLC1A6 STAT3 LUZP1 SRGAP1	1.42e-06	200	177	8	a02fa5b3c4723a6eaa3c685588666c710478dd25
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MAP1A FOLH1 SH3GL3 ABCA8 SORT1 CRYAB DOCK5 TMEM151A	1.42e-06	200	177	8	acdef0b9096c774040948fc75621ff2b08ea2ee8
ToppCell	LPS_IL1RA-Endothelial\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	UACA RPS6KA2 ARHGEF12 RNF213 LUZP1 ARHGAP29 MACF1 DOCK6	1.42e-06	200	177	8	5c092b2ecc081b5d04476c56333c338cd89ab984
ToppCell	LPS_only-Endothelial\|LPS_only / Treatment groups by lineage, cell group, cell type	UACA RPS6KA2 ARHGEF12 LUZP1 NR5A2 ARHGAP29 MACF1 DOCK6	1.42e-06	200	177	8	81e76508c9050d533853d5fd2f3097b27613d836
ToppCell	COVID-19\|World / Disease, condition lineage and cell class	SP100 CDV3 RNF213 STAT3 ANKRD11 MACF1 ROCK1 CNOT1	1.42e-06	200	177	8	7dec470c379cd89f05a0f37c8628b21f136e52f0
ToppCell	LPS_only-Endothelial-Endothelial\|LPS_only / Treatment groups by lineage, cell group, cell type	UACA RPS6KA2 ARHGEF12 LUZP1 NR5A2 ARHGAP29 MACF1 DOCK6	1.42e-06	200	177	8	4bb609a284d4e6066f17470a1736076aa4a1f84c
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	RIPOR2 CTTNBP2 ADAM10 OPHN1 GREB1L CRYAB ARHGAP29	7.33e-06	178	177	7	c20f050344a2e120e685e2a7fe36c6dfc1dc37b6
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPHB2 RIPOR2 CTTNBP2 MNS1 ADAM10 ARHGAP29 EPHA4	8.79e-06	183	177	7	cfae90c309622b5d499e62a3a8a8b9746478d28d
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Inner_Medullary_Collecting_Duct_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYH10 PTCHD3 MNS1 SPTBN2 RNF213 GREB1L PKM	9.43e-06	185	177	7	a6874dd3030d04380cc3c01de1069461aad4ef45
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Outer_Medullary_Collecting_Duct_Principal_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYH10 MNS1 MYO1E SPTBN2 MBOAT2 OPHN1 GREB1L	1.01e-05	187	177	7	e3095455d2f255854f339f6b05fa87852af0700f
ToppCell	droplet-Heart-nan-3m-Endothelial-endocardial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RIPOR2 RPS6KA2 CERT1 DNAH1 GREB1L ARHGAP29 DOCK6	1.08e-05	189	177	7	8e583ec4df0f5b79ce5211cc99ecd8616d180bde
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MYH10 MXRA5 MNS1 MYO1E SPTBN2 MBOAT2 GREB1L	1.08e-05	189	177	7	fc88c51ace7d883c01617f3f9b5fab70cc91cc09
ToppCell	LA-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	MYH10 MYO1E TASP1 ITPR1 SORT1 MACF1 ROCK1	1.08e-05	189	177	7	6b3e88751b95fc2173f2c3d5061ed632d0c5f01c
ToppCell	renal_papilla_nuclei-Adult_normal_reference\|renal_papilla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	SH3GL3 OPHN1 ITPR1 SORT1 GREB1L CRYAB EPHA4	1.20e-05	192	177	7	6c106b91e46eabbe686a52a65a9c94ad9cbe9390
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-D\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SERPINA3 MAP1A ABCA8 SORT1 CRYAB DOCK5 TMEM151A	1.24e-05	193	177	7	947200ef6c3a2e35ad7e6b4af29d92384bdf73f5
ToppCell	COVID-19-Heart-EC_1\|Heart / Disease (COVID-19 only), tissue and cell type	UACA MYO1E F8 NR5A2 ARHGAP29 GNAQ EPHA4	1.33e-05	195	177	7	50a193475db1bb1e05b8590225a553688c372c14
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	MYH10 MXRA5 CCDC80 ABCA8 SRGAP1 FADS2 MACF1	1.42e-05	197	177	7	fdb92985f7df0c280b87d3e43c2394e70786a2c7
ToppCell	COVID-19_Severe-PLT_0\|COVID-19_Severe / Disease Group and Platelet Clusters	MAP1A VPS8 ARHGEF12 SORT1 PKM MACF1 GNAQ	1.42e-05	197	177	7	dbdeefa72d10f2c5f75ad5aac6f31a892d4e94a9
ToppCell	COVID-19_Severe-PLT_0\|World / Disease Group and Platelet Clusters	MAP1A HTATIP2 VPS8 ARHGEF12 SORT1 PKM MACF1	1.46e-05	198	177	7	d508d69d8de233573aee14f17dd8ef054654aa54
ToppCell	systemic_lupus_erythematosus-flare\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	SP100 RIPOR2 RNF213 CEP78 ATF7IP MACF1 ROCK1	1.46e-05	198	177	7	4c93ee921d56132d80832d8e94563f32ccf13bbc
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-G\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FOLH1 SH3GL3 ABCA8 SORT1 CRYAB DOCK5 TMEM151A	1.46e-05	198	177	7	bdabdb11217ea16e5863aa6bfb0f04d48b17f81e
ToppCell	(10)_Ciliated-(2)_GFP_FOXI1\|(10)_Ciliated / shred by cell type by condition	MNS1 UACA CNTRL NIPSNAP2 ABCC9 ANKRD11 ROCK1	1.51e-05	199	177	7	61b1ed2db71b96157b92b7535d1955a4033098da
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FOLH1 SH3GL3 ABCA8 SORT1 CRYAB DOCK5 TMEM151A	1.51e-05	199	177	7	214a6a267e77e5508867b9eb48c4fbc7855ed0a0
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	NAALAD2 MYH10 CCDC80 ABCA8 SRGAP1 FADS2 MACF1	1.51e-05	199	177	7	30d3e8c0681ec11f86dd38c5f48d21187a1b4f90
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	UACA ARHGEF12 RNF213 NR5A2 ARHGAP29 MACF1 DOCK6	1.56e-05	200	177	7	dccec522ab0d7fff62ad6273b02aa9022dbbb8eb
ToppCell	medial-mesenchymal-Alveolar_Fibroblast\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	SERPINA3 MYH10 CCDC80 ABCA8 CRYAB SRGAP1 MACF1	1.56e-05	200	177	7	c22cbfecee00183dd4be678f116ab9fd9ad0a4dd
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Activated_Gen_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	MYO1E RPS6KA2 ARHGEF12 RNF213 LUZP1 NR5A2 MACF1	1.56e-05	200	177	7	2d07237022b409c4fac6fcf99b68c8affb3007cd
ToppCell	LPS_only-Endothelial-Endothelial-Gen_Cap\|LPS_only / Treatment groups by lineage, cell group, cell type	UACA RPS6KA2 ARHGEF12 NR5A2 ARHGAP29 MACF1 DOCK6	1.56e-05	200	177	7	eb94a5111ef0e903ee5be9f7efe571b4e6d5fce1
ToppCell	LPS_only-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_only / Treatment groups by lineage, cell group, cell type	UACA MYO1E ARHGEF12 RNF213 LUZP1 ARHGAP29 MACF1	1.56e-05	200	177	7	edb64556b3fefe3144f73b6efe23b9ffd34091d2
ToppCell	medial-2-mesenchymal-Alveolar_Fibroblast\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	SERPINA3 MYH10 CCDC80 ABCA8 CRYAB SRGAP1 MACF1	1.56e-05	200	177	7	cc6062dac07916c29091fc6bee2b864d29e6525b
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FOLH1 SH3GL3 ABCA8 SORT1 CRYAB DOCK5 TMEM151A	1.56e-05	200	177	7	091a18d6efed81cab99955c3047f172170f70476
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FOLH1 SH3GL3 ABCA8 SORT1 CRYAB DOCK5 TMEM151A	1.56e-05	200	177	7	3b8513defe25262ab4b492345b2628570eaefd17
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	UACA ARHGEF12 RNF213 ADAM10 LUZP1 ARHGAP29 MACF1	1.56e-05	200	177	7	79e51afb57ca38aacebd0298e5e727b55c0cfff9
ToppCell	mild\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	SP100 CDV3 RNF213 ATF7IP ANKRD11 MACF1 ROCK1	1.56e-05	200	177	7	12f1685ce8f218433068e090c9d839cd5a1910bf
ToppCell	medial-mesenchymal-Alveolar_Fibroblast-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	SERPINA3 MYH10 CCDC80 ABCA8 CRYAB SRGAP1 MACF1	1.56e-05	200	177	7	5c0716bf375c8158f7dc2c82bf5eaf37af594dd0
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	UACA RPS6KA2 ARHGEF12 RNF213 LUZP1 ARHGAP29 DOCK6	1.56e-05	200	177	7	a1fa6bae5a688faf488d6925cd3fad725dfa916b
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FOLH1 SH3GL3 ABCA8 SORT1 CRYAB DOCK5 TMEM151A	1.56e-05	200	177	7	0bfd41c12887479ceb62c3db0a3c3ba5007eb62b
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FOLH1 SH3GL3 ABCA8 SORT1 CRYAB DOCK5 TMEM151A	1.56e-05	200	177	7	159377d904394d91e09913131e9a93e08189955a
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FOLH1 SH3GL3 ABCA8 SORT1 CRYAB DOCK5 TMEM151A	1.56e-05	200	177	7	d30316836494f33ca46d4e415fd2ed179e9cb5ee
ToppCell	LPS_IL1RA_TNF-Endothelial\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	UACA RPS6KA2 ARHGEF12 RNF213 LUZP1 ARHGAP29 DOCK6	1.56e-05	200	177	7	d01cec331be3b03cef80e9536fc531285bcf00f6
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial-Activated_Gen_Cap\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	SP100 MYO1E ARHGEF12 RNF213 NR5A2 ARHGAP29 DOCK6	1.56e-05	200	177	7	3585484c7e24e941708bee471ca607d8ccee74e6
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-F\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FOLH1 SH3GL3 ABCA8 SORT1 CRYAB TLL2 TMEM151A	1.56e-05	200	177	7	829978708463a7459fe1041bd90196775bc4b531
ToppCell	10x5'-GI_large-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_large-bowel / Manually curated celltypes from each tissue	MAP1A CCDC80 CENPP CEP78 SEC14L4 PNMA3	3.28e-05	152	177	6	95944864ce7539ff8de028f5700694931338f3ff
ToppCell	TCGA-Endometrium-Primary_Tumor-Endometrial_Adenocarcinoma-Serous_adenocarcinoma\|TCGA-Endometrium / Sample_Type by Project: Shred V9	EPHB2 CCDC150 FCHO1 RYR1 ARHGAP29 PNMA3	5.02e-05	164	177	6	08c725548e751f815b4df778607270498204b353
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_G2M\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	BRIP1 NDE1 CCDC150 FCHO1 CENPP KNL1	5.02e-05	164	177	6	1642a67c66eeb77a218e7814e3cfe517d9822955
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	BRIP1 NDE1 CCDC150 FCHO1 CENPP KNL1	5.02e-05	164	177	6	25758fb8112baf296264122d5d4121f1ebb3d0fa
ToppCell	mild_COVID-19_(asymptomatic)-pDC\|World / disease group, cell group and cell class (v2)	MAP1A MYO1E RPS6KA2 TRIP10 UCK2 TMEM151A	5.55e-05	167	177	6	bf08f17965a4dd03f371b4ed0ab0d5e62ed61307
ToppCell	saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	SPP2 MAFA DNAH1 DNAH12 MAPK15 CROCC	5.74e-05	168	177	6	9a8709d34865cfa668d8f3335dc34fc86fc32482
ToppCell	343B-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	BICRA RPS6KA2 BMS1 DENND2B CROCC TAFAZZIN	6.54e-05	172	177	6	d65ffff3e341af34a043a0d802d7ba4b69de36e9
ToppCell	facs\|World / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SP100 ADAM10 ATF7IP FADS2 MAST1 GNAQ	6.54e-05	172	177	6	a2d0a64ebf09d219a07d6bbad1056bad6d46b9be
ToppCell	5'-Adult-Appendix-Mesenchymal-fibroblastic-Stromal_1_(CCL11+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MXRA5 MYH13 RPS6KA2 DENND2B ABCA8 CRYBG3	6.97e-05	174	177	6	f90ca117b729436cf452e2ddcec26ba525c5c13b
ToppCell	TCGA-Liver\|World / Sample_Type by Project: Shred V9	CYP2A6 SPP2 CYP4A11 APOB CYP4A22 GYS2	6.97e-05	174	177	6	452932f08cf53e5949672a025d78cecb874aa4b0
ToppCell	TCGA-Colorectal-Recurrent_Tumor\|TCGA-Colorectal / Sample_Type by Project: Shred V9	SERPINA3 CYP2A6 SPP2 CYP4A11 CYP4A22 GYS2	7.19e-05	175	177	6	7f74961436f88c0e380819095e6104489914d765
ToppCell	TCGA-Colorectal-Recurrent_Tumor-Colorectal_Adenocarcinoma\|TCGA-Colorectal / Sample_Type by Project: Shred V9	SERPINA3 CYP2A6 SPP2 CYP4A11 CYP4A22 GYS2	7.19e-05	175	177	6	bee8f31f036dfcf9fc6ed29156554771a9ee3c60
ToppCell	saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	CNTRL DENND2B ABCA8 DUOX1 DNAJC14 KNL1	7.42e-05	176	177	6	e08e7a6dd0208acfbb8646d71915af822a64b5de
ToppCell	saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic-conventional_dendritic_cell\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	CNTRL DENND2B ABCA8 DUOX1 DNAJC14 KNL1	7.42e-05	176	177	6	b8264cdda75c5145d8bf8ae00b3e05393fe9a92b
ToppCell	saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic-conventional_dendritic_cell-DC_c2-CD1C\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	CNTRL DENND2B ABCA8 DUOX1 DNAJC14 KNL1	7.42e-05	176	177	6	4aee9fdada077db7e531684ab938153f84dc8146
ToppCell	droplet-Limb_Muscle-MUSCLE-30m\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SP100 CDK12 CNTRL LUZP1 ANKRD11 ARHGAP29	7.90e-05	178	177	6	01dafd19de04eff459253eaa9a35debf8f3deedf
ToppCell	facs-Brain_Non-Myeloid-Striatum-24m-Neuronal-neuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CELF5 MAP1A SPTBN2 RYR1 ITPR1 PNMA3	7.90e-05	178	177	6	a74e5a390cbeaca9de1fdb7b2a0e50783bd202dd
ToppCell	facs-Brain_Non-Myeloid-Striatum-24m-Neuronal-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CELF5 MAP1A SPTBN2 RYR1 ITPR1 PNMA3	7.90e-05	178	177	6	1bddbc083c36657bd6910f7466126ab325e88176
ToppCell	3'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_differentiating-Lymphatic_EC_differentiating_L.2.5.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYH10 F8 DOCK5 ARHGAP29 MACF1 DOCK6	7.90e-05	178	177	6	ad3de3e03a401dac64431a541899445262246347
ToppCell	COVID-19-kidney-AQP1+SLC14A1+EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	MYO1E RPS6KA2 F8 ARHGAP29 DOCK6 EPHA4	8.15e-05	179	177	6	1ce8d18f63e8dd2d3db41fbeca4601bd3b305fba
ToppCell	LPS-IL1RA-Endothelial-Endothelial-FOXM1\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	BRIP1 ZGRF1 CCDC150 CENPP NR5A2 KNL1	8.40e-05	180	177	6	334e2b1f6eb7d4ece20b1c7b02107863f913237f
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte-Oligo_L4-6_MOBP_COL18A1\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MYH6 MYO1E FOLH1 ABCA8 CRYAB DOCK5	8.66e-05	181	177	6	a8e9ea73c24109a5d4d28bc0577cc869ad932a4d
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NAALAD2 MYH10 CTTNBP2 UACA ABCA8 SRGAP1	8.66e-05	181	177	6	9ede19228ba5c0668a9c06c915510b95585216ef
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte-Oligo_L4-6_MOBP_COL18A1\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MYO1E NDE1 FOLH1 ABCA8 CRYAB DOCK5	8.93e-05	182	177	6	d524ad5cf00f05ee27c9db2ffa2d4e30a1e2e21a
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Principal_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYH10 MXRA5 MNS1 MYO1E SPTBN2 OPHN1	8.93e-05	182	177	6	f96095b81188b52db8fcfca4837129cfcd9bd7b7
ToppCell	Ciliated_cells-B-Donor_04\|World / lung cells shred on cell class, cell subclass, sample id	MNS1 MAP1A SH3GL3 CCDC80 DNAH12 SEC14L4	8.93e-05	182	177	6	e93968f800bfeb258e4e834fc8bf92d1cb72cd73
ToppCell	RA-13._Vascular_Smooth_Muscle\|RA / Chamber and Cluster_Paper	MYH10 MYO1E TASP1 ITPR1 SORT1 ROCK1	9.20e-05	183	177	6	818fd886e0188091310825f9145fa53328f2c979
ToppCell	Control-Endothelial-Endothelial-Activated_Alv_Cap\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SP100 UACA RNF213 MBOAT2 SRGAP1 DAAM1	9.20e-05	183	177	6	e81c142770f44fd902b0631bc360c5b5339d4c75
ToppCell	RA-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	MYH10 MYO1E NDE1 TASP1 ITPR1 SORT1	9.20e-05	183	177	6	cae2ee08f985a6f005b4b8e959e465350315156a
ToppCell	COVID-19-Neuronal_cells-Neuronal_cells\|COVID-19 / group, cell type (main and fine annotations)	ADAM10 F8 DOCK5 NR5A2 ARHGAP29 DOCK6	9.76e-05	185	177	6	4a095829992b39856a73bdfac03ee68b9aa0d3b8
ToppCell	droplet-Heart-4Chambers-21m-Endothelial-leukocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CTTNBP2 SH3GL3 MAGEE2 F8 SCN5A KNL1	9.76e-05	185	177	6	bb5a4cf93534b9bcd0923f314c389d571e91e7f8
ToppCell	COVID-19-Neuronal_cells\|COVID-19 / group, cell type (main and fine annotations)	ADAM10 F8 DOCK5 NR5A2 ARHGAP29 DOCK6	9.76e-05	185	177	6	36ce23893915f5c380cca39b2c33a516edf31c3a
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	RIPOR2 CTTNBP2 ADAM10 CRYAB PKM ARHGAP29	1.01e-04	186	177	6	3dae539cce15fcf2b1b32e981d7febe94c03c600
ToppCell	Frontal_cortex-Endothelial\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	SP100 NAALAD2 UACA TRIP10 ARHGAP29 DOCK6	1.07e-04	188	177	6	a43392dbd10fc7dbfb31be39b8af8a7ea121c894
ToppCell	Frontal_cortex-Neuronal-Inhibitory-iN2(Gad1Gad2)-Cplx3-Inhibitory_Neuron.Gad1Gad2.Cplx3-Crim1_(Neuron.Gad1Gad2.Cplx3-Crim1)-\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	CCDC150 RSPH6A GYS2 SPINK5	1.08e-04	62	177	4	91c49ae176d2a418a58398e9d5e55c77187cc2fb
ToppCell	Frontal_cortex-Neuronal-Inhibitory-iN2(Gad1Gad2)-Cplx3-Inhibitory_Neuron.Gad1Gad2.Cplx3-Crim1_(Neuron.Gad1Gad2.Cplx3-Crim1)\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	CCDC150 RSPH6A GYS2 SPINK5	1.08e-04	62	177	4	3275775572a65460b6248ee72b4c85e4d4dee424
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYH10 MXRA5 MNS1 SPTBN2 MBOAT2 GREB1L	1.10e-04	189	177	6	3a295c215b5c18e7c673f92b7af5be523421682c
ToppCell	10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-B_lymphocytic-naive_B_cell\|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	SP100 UACA MYO7B PEG10 ITPR1 ATF7IP	1.10e-04	189	177	6	e2bb5900d210386b7b74938e7a3636d0c7ba1bcf
ToppCell	Striatum-Endothelial\|Striatum / BrainAtlas - Mouse McCarroll V32	NAALAD2 UACA ABCC9 TRIP10 ARHGAP29 DOCK6	1.10e-04	189	177	6	95ee3b6d7fbbfcf91c780dfcd0926acec05f0a2d
ToppCell	Control-Endothelial-Endothelial-FOXM1\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	BRIP1 NDE1 ZGRF1 CCDC150 CENPP KNL1	1.10e-04	189	177	6	1e1499b062d9c647c8f38b0c4e0d871d159be5dd
ToppCell	droplet-Heart-nan-3m-Endothelial-endocardial_endothelial_cells\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RIPOR2 RPS6KA2 CERT1 DNAH1 GREB1L DOCK6	1.10e-04	189	177	6	fb2253b8463d08b3d28e952a31a23dea2c2d986b
ToppCell	Children_(3_yrs)-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	UACA ARHGEF12 DENND2B ARHGAP29 DAAM1 DOCK6	1.13e-04	190	177	6	0e9847d7f49b2236b8a191e1a7df37556351ba9e
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-B_lymphocytic-naive_B_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	SP100 RIPOR2 MYO7B ITPR1 SP140L ATF7IP	1.13e-04	190	177	6	a7498fe55b7810c482291db782dc5282675d246a
ToppCell	pdx-Tumor_cells-T1\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	BRIP1 NDE1 ZGRF1 MSH2 CENPP KNL1	1.13e-04	190	177	6	d06ee5f89f1cec8db6897fe3b2a890a07cd3697b
ToppCell	droplet-Large_Intestine-COLON_PROXIMAL\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CDV3 CNTRL APOB ADAM10 UBTF ANKRD11	1.16e-04	191	177	6	60c986d2dcbc19d9338c03da6cb5e1d92fd48f8e
ToppCell	(04)_Pre-ciliated\|World / shred by cell type and Timepoint	PTCHD3 MNS1 MAP1A MBOAT2 MAPK15 CEP78	1.16e-04	191	177	6	37cf121e6e80760c8519075b7845b9029958a988
ToppCell	ASK454-Mesenchymal\|ASK454 / Donor, Lineage and Cell class of Lung cells from Dropseq	NAALAD2 MYH10 MXRA5 UACA CCDC80 SRGAP1	1.16e-04	191	177	6	e30ae7a12439f8a79820b13f03e822c1223fd0cb
ToppCell	ASK454-Mesenchymal-Fibroblast\|ASK454 / Donor, Lineage and Cell class of Lung cells from Dropseq	NAALAD2 MYH10 MXRA5 UACA CCDC80 SRGAP1	1.16e-04	191	177	6	1726add3f392a061536b7aff72ba84303f4a0b1f
Drug	B0683	MYH4 MYH6 MYH10 MYH13 MYO1E ACTR1A GLUD1 GLUD2 ROCK1	3.24e-07	117	176	9	CID006398969
Drug	2bq7	SERPINA3 CYP2A6 MYH4 MYH6 MYH10 MYH13 CYP4A11 DENND2B F8	4.96e-07	123	176	9	CID006540267
Drug	methenamine silver	SERPINA3 TASP1 ARHGEF12 APOB TRIP10 GDNF ACTR1A SRGAP1 ROCK1 DAAM1 KNL1	4.96e-07	201	176	11	CID000004101
Drug	dicyclohexyl phthalate	CYP2A6 MYH4 CYP2A13 CAD UACA RC3H1 ARHGEF12 ABCC5 APOB MSH2 CPT1A ADAM10 STAT3 ITPR1 SORT1 CRYAB PPARGC1B DUOX1 CTR9 PKM ASB4 CNOT1	5.54e-07	836	176	22	ctd:C036042
Drug	S-(-)-Etomoxir	MYH4 MYH6 MYH10 MYH13 MYO1E CYP4A11 CPT1A FDFT1	1.10e-06	100	176	8	CID000060765
Drug	eye gene	MYH4 MYH6 MYH10 EVC2 MYH13 MYO1E CYP4A11 PEG10 ACTR1A MAPK15 UBTF GYS2 ROCK1 GNAQ	1.16e-06	369	176	14	CID000004782
Drug	8-BDB-TADP	GLUD1 GLUD2 PKM	1.81e-06	4	176	3	CID000130791
Drug	luxabendazole	GLUD1 GLUD2 PKM	1.81e-06	4	176	3	CID000072019
Drug	AlaGlu	NAALAD2 FOLH1 GLUD1 GLUD2	2.34e-06	13	176	4	CID000128841
Drug	Canavanine sulfate monohydrate (L,+) [206996-57-8]; Down 200; 13.6uM; MCF7; HT_HG-U133A	RALB BRIP1 SPAST RPS6KA2 HTATIP2 TASP1 MSH2 SUGP2 MACF1 PCMTD2	3.12e-06	196	176	10	4782_DN
Drug	4-chloroaniline	SERPINA3 MYH4 MYH6 MYH10 MYH13 FOLH1 RYR1 STAT3 SORT1 ROCK1	4.09e-06	202	176	10	CID000007812
Drug	l-413	CAD GLUD1 GLUD2	4.49e-06	5	176	3	CID000012475
Drug	nifedipine	CYP2A6 MYH4 MYH6 CYP2A13 MYH10 MYH13 CYP4A11 NBN RYR1 CYP4A22 ITPR1 FADS2 UCK2 ROCK1	4.56e-06	415	176	14	CID000004485
Drug	SM-2	MYH4 MYH6 MYH10 MYH13 FDFT1 GLUD1 GLUD2	5.08e-06	87	176	7	CID000486033
Drug	lanosol	CYP2A6 GLUD1 GLUD2	8.93e-06	6	176	3	CID000078659
Drug	diazonium-1-H-tetrazole	NBN GLUD1 GLUD2	8.93e-06	6	176	3	CID000188312
Drug	2-BDB-TAMP	GLUD1 GLUD2 PKM	8.93e-06	6	176	3	CID000127220
Drug	AC1L196J	CYP2A6 CYP2A13 GYS2	8.93e-06	6	176	3	CID000000415
Drug	2 pc	ERBB4 GLUD1 GLUD2 TAFAZZIN	9.70e-06	18	176	4	CID000440046
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A	MAP1A MYO1E KIAA0513 RPS6KA2 SH3GL3 ZNF365 LUZP1 ITPR1 UNC119	1.16e-05	180	176	9	2639_UP
Drug	glutamin	SP100 CAD SPAST SPTBN2 SH3GL3 NBN MSH2 TRIP10 SLC1A6 ITPR1 CRYAB GLUD1 GLUD2 ROCK1	1.49e-05	461	176	14	CID000000738
Drug	Tetracycline	SERPINA3 NAALAD2 CAD RPS6KA2 HTATIP2 NBN APOB CPT1A STAT3 CYP4A22 EPG5 CRYAB FDFT1 GYS2 GLUD1 SEC14L4 KNL1	1.79e-05	668	176	17	ctd:D013752
Drug	Ethopropazine hydrochloride [1094-08-2]; Down 200; 11.4uM; PC3; HT_HG-U133A	EPHB2 NAALAD2 BICRA RPS6KA2 CNTRL HTATIP2 ITPR1 ZFYVE9 ARHGEF4	2.01e-05	193	176	9	6697_DN
Drug	Fusidic acid sodium salt [751-94-0]; Up 200; 7.4uM; HL60; HT_HG-U133A	CUL4B SP100 CDV3 BRIP1 PDE6D SPAST NCBP1 CPT1A ADAM10	2.10e-05	194	176	9	1293_UP
Drug	Carbenoxolone disodium salt [7421-40-1]; Down 200; 6.6uM; MCF7; HT_HG-U133A	UTP6 RPS6KA2 SPTBN2 DOCK5 SUGP2 ARHGEF4 CROCC TAFAZZIN SPINK5	2.28e-05	196	176	9	3353_DN
Drug	Gly-His-Lys acetate salt; Down 200; 1uM; PC3; HT_HG-U133A	NDE1 SPTBN2 ARHGEF12 CPT1A ANKZF1 FCHO1 LETM1 DIMT1 ARHGEF4	2.37e-05	197	176	9	6570_DN
Drug	Paromomycin sulfate [1263-89-4]; Down 200; 5.6uM; MCF7; HT_HG-U133A	RPS6KA2 CUL9 NCBP1 DENND2B ITPR1 DOCK5 ZFYVE9 TAFAZZIN CPSF7	2.47e-05	198	176	9	3356_DN
Drug	Pindolol [13523-86-9]; Up 200; 16.2uM; HL60; HG-U133A	RALB PDE6D TASP1 CERT1 FCHO1 LETM1 DOCK5 EID1 TAFAZZIN	2.47e-05	198	176	9	1392_UP
Drug	5162773; Up 200; 7uM; MCF7; HT_HG-U133A_EA	EPHB2 RALB OTUD7B SORT1 GREB1L DIMT1 ARHGEF9 FADS2 ARHGEF4	2.57e-05	199	176	9	892_UP
Drug	blebbistatin	MYH4 MYH6 MYH10 MYH13 MYO1E ACTR1A ROCK1	3.36e-05	116	176	7	CID003476986
Drug	AC1L9EF8	RNPC3 ZNF365 F8 ACTR1A FDFT1 ANKRD11	3.41e-05	79	176	6	CID000443315
Drug	formycin triphosphate	MYH4 MYH6 MYH10 MYH13 MYO1E	4.59e-05	51	176	5	CID000122274
Drug	felodipine	CYP2A6 CYP2A13 PDE6D CYP4A11 RYR1 CYP4A22 ITPR1 EPHA4	5.27e-05	169	176	8	CID000003333
Drug	cariporide	PEG10 NBN STAT3 SLC4A2 ROCK1 GNAQ	5.52e-05	86	176	6	CID000151172
Drug	phenyltriethoxysilane	GLUD1 GLUD2	5.94e-05	2	176	2	CID000013075
Drug	propargyl ether	CYP2A6 CYP2A13	5.94e-05	2	176	2	ctd:C531209
Drug	Hempa	CYP2A6 CYP2A13	5.94e-05	2	176	2	ctd:D006492
Drug	G-3SH	GLUD1 GLUD2	5.94e-05	2	176	2	CID000174237
Drug	iodoacetyldiethylstilbestrol	GLUD1 GLUD2	5.94e-05	2	176	2	CID006455327
Drug	methylmercuric bromide	GLUD1 GLUD2	5.94e-05	2	176	2	CID000068175
Drug	5-methylisophthalate	GLUD1 GLUD2	5.94e-05	2	176	2	CID000068137
Drug	nicotine imine	CYP2A6 CYP2A13	5.94e-05	2	176	2	ctd:C034629
Drug	alpha-nicotyrine	CYP2A6 CYP2A13	5.94e-05	2	176	2	ctd:C008615
Drug	x 1 s	GLUD1 GLUD2	5.94e-05	2	176	2	CID000409694
Drug	N-nitrosoguvacoline	CYP2A6 CYP2A13	5.94e-05	2	176	2	ctd:C036676
Drug	14(15)-EpETrE	CYP2A6 CYP2A13 CYP4A11 CPT1A STAT3 GNAQ	6.69e-05	89	176	6	CID000001431
Drug	AC1LADJ6	MYH4 MYH6 MYH10 MYH13 ACTR1A GLUD1 GLUD2	6.96e-05	130	176	7	CID000486032
Drug	sulfoacetic acid	TRNT1 GLUD1 GLUD2	7.16e-05	11	176	3	CID000031257
Drug	8-amino-cADPR	RYR1 ITPR1 GNAQ	7.16e-05	11	176	3	CID003081323
Drug	Trichostatin A, Streptomyces sp.; Up 200; 1uM; HL60; HT_HG-U133A	EPHB2 PDE6D KIAA0513 VPS8 UNC119 ARHGAP29 GNA11 DAAM1	7.90e-05	179	176	8	2694_UP
Drug	purealin	MYH4 MYH6 MYH10 MYH13 MYO1E	8.58e-05	58	176	5	CID006419303
Drug	nocodazole	MYH4 MYH6 MYH10 MYH13 MNS1 MAP1A NDE1 ITPR1 DOCK5 ACTR1A ROCK1 PCMTD2 ZW10	9.13e-05	477	176	13	CID000004122
Drug	carbachol	MYH4 MYH6 ERBB4 MYH10 MYH13 PEG10 RPS6KA2 TASP1 NBN RYR1 ITPR1 ACTR1A MAPK15 ROCK1 GNA11 GNAQ	9.24e-05	688	176	16	CID000002551
Drug	C16:1n-7	CYP4A11 APOB PPARGC1B ANKRD11 FADS2	9.31e-05	59	176	5	CID000004668
Drug	Adamantamine fumarate [80789-67-9]; Down 200; 9.6uM; HL60; HT_HG-U133A	CDV3 BRIP1 UPF1 ADAM10 CERT1 ITPR1 DIMT1 ROCK1	9.57e-05	184	176	8	1344_DN
Drug	AC1NS44W	ERBB4 NLRP2 STAT3 SORT1 MAPK15	1.01e-04	60	176	5	CID005353385
Drug	MgCl2	MYH4 MYH6 MYH10 MYH13 MYO1E SPTBN2 ACTR1A FDFT1 GLUD2 FADS2 GNAQ	1.03e-04	354	176	11	CID000024584
Drug	clenbuterol	MYH4 MYH6 MYH10 MYH13 MYO1E RPS6KA2 GSDME	1.21e-04	142	176	7	CID000002783
Drug	5-hydroxythiabendazole	CYP4A11 GLUD1 GLUD2	1.23e-04	13	176	3	CID000108227
Drug	NSC226080	CUL4B MYH4 MYH6 ERBB4 MYH10 MYH13 RPS6KA2 TASP1 NCBP1 UPF1 RYR1 STAT3 ITPR1 DOCK5 MAPK15 GYS2 ROCK1	1.25e-04	782	176	17	CID000005040
Drug	Hypertensin II	MYH6 EVC2 CYP4A11 PEG10 APOB GDNF STAT3 MAPK15 UBTF SCN5A ROCK1 GNAQ	1.34e-04	429	176	12	CID000025476
Drug	glutarate	SP100 NAALAD2 FOLH1 ABCC5 GLUD1 GLUD2	1.35e-04	101	176	6	CID000000743
Drug	allyl alcohol	NBN NLRP2 FDFT1 GLUD1 GLUD2	1.37e-04	64	176	5	CID000007858
Drug	Cyanocobalamin [68-19-9]; Down 200; 3uM; PC3; HT_HG-U133A	EPHB2 RPS6KA2 ARHGEF12 CUL9 CPT1A ANKZF1 GREB1L ROCK1	1.38e-04	194	176	8	4572_DN
Drug	Riluzole hydrochloride; Down 200; 14.8uM; MCF7; HT_HG-U133A	RALB CDV3 BRIP1 ZNF365 F8 ITPR1 UNC119 TAFAZZIN	1.38e-04	194	176	8	2295_DN
Drug	NSC107658	MYH4 MYH6 MYH10 MYH13 MNS1 MYO1E TASP1 ACTR1A PKM ROCK1	1.41e-04	306	176	10	CID000002919
Drug	5211181; Up 200; 12uM; MCF7; HT_HG-U133A_EA	SP100 MYO1E ZNF365 ITPR1 ZFYVE9 DIMT1 FADS2 ARHGEF4	1.43e-04	195	176	8	834_UP
Drug	Ranitidine hydrochloride [66357-59-3]; Down 200; 11.4uM; MCF7; HT_HG-U133A	CUL4B CDV3 BRIP1 CPT1A ADAM10 SORT1 DOCK5 MACF1	1.48e-04	196	176	8	5425_DN
Drug	Amikacin hydrate [37517-28-5]; Down 200; 6.6uM; MCF7; HT_HG-U133A	BICRA CUL9 ADAM10 ZNF365 LUZP1 UNC119 DIMT1 FADS2	1.48e-04	196	176	8	3233_DN
Drug	N-Acetyl-L-leucine [1188-21-2]; Down 200; 23uM; MCF7; HT_HG-U133A	SERPINA3 RPS6KA2 ANKZF1 ADAM10 ZNF365 DOCK5 UBTF IGSF1	1.48e-04	196	176	8	6462_DN
Drug	nordihydroguaiaretic acid; Up 200; 1uM; MCF7; HT_HG-U133A	MXRA5 RYR1 ITPR1 GREB1L NR5A2 CROCC TAFAZZIN SPINK5	1.48e-04	196	176	8	5583_UP
Drug	Indapamide [26807-65-8]; Down 200; 10.6uM; HL60; HT_HG-U133A	SP100 DNAJC13 UPF1 LETM1 LUZP1 SLC4A2 UBTF MACF1	1.48e-04	196	176	8	2361_DN
Drug	NSC339663	MYH4 MYH6 MYH10 MYH13 MYO1E ACTR1A MAPK15 ROCK1 GNAQ	1.49e-04	250	176	9	CID000003892
Drug	ICI 182,780; Up 200; 1uM; MCF7; HG-U133A	KIAA0513 ANKZF1 LUZP1 GREB1L CRYAB FADS2 CROCC EPHA4	1.53e-04	197	176	8	367_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	SP100 HTATIP2 NBN UPF1 ANKZF1 DIMT1 SUGP2 UBTF	1.53e-04	197	176	8	6222_DN
Drug	Heliotrine [303-33-3]; Down 200; 12.8uM; MCF7; HT_HG-U133A	EPHB2 CNTRL ARHGEF12 CUL9 NCBP1 DENND2B ITPR1 SORT1	1.53e-04	197	176	8	3615_DN
Drug	LY 294002; Down 200; 0.1uM; HL60; HT_HG-U133A	NBN ANKZF1 LETM1 SLC4A2 UNC119 GNA11 ZW10 NR1D2	1.53e-04	197	176	8	6175_DN
Drug	ws 10	GLUD1 GLUD2 PKM	1.55e-04	14	176	3	CID000107151
Drug	Sulcrate	SERPINA3 NBN NLRP2 GDNF GLUD1 GLUD2 GNAQ	1.57e-04	148	176	7	CID006398525
Drug	Xylometazoline hydrochloride [1218-35-5]; Down 200; 14.2uM; PC3; HT_HG-U133A	MYH10 PEG10 RPS6KA2 NCBP1 UPF1 FCHO1 SUGP2 MACF1	1.59e-04	198	176	8	2107_DN
Drug	Urosiol [128-13-2]; Down 200; 10.2uM; PC3; HT_HG-U133A	SP100 CDV3 NDE1 HTATIP2 ARHGEF12 ITPR1 KDM4A TAFAZZIN	1.59e-04	198	176	8	7243_DN
Drug	Famotidine [76824-35-6]; Down 200; 11.8uM; PC3; HT_HG-U133A	KIAA0513 RPS6KA2 ARHGEF12 ABCC5 ZFYVE9 ARHGEF4 ZW10 TAFAZZIN	1.64e-04	199	176	8	6665_DN
Drug	Oxymetazoline hydrochloride [2315-02-8]; Up 200; 13.4uM; MCF7; HT_HG-U133A	MAP1A NDE1 RPS6KA2 GREB1L CRYAB ZFYVE9 TAFAZZIN SPINK5	1.70e-04	200	176	8	2278_UP
Drug	lenthionine	GLUD1 GLUD2	1.77e-04	3	176	2	CID000067521
Drug	mildiomycin	GLUD1 GLUD2	1.77e-04	3	176	2	CID000125665
Drug	methoxyethylmercury	GLUD1 GLUD2	1.77e-04	3	176	2	CID000115155
Drug	4-methylumbelliferyl laurate	GLUD1 GLUD2	1.77e-04	3	176	2	CID000600674
Drug	methylmercuric iodide	GLUD1 GLUD2	1.77e-04	3	176	2	CID000067347
Drug	2'-methoxyacetophenone	CYP2A6 CYP2A13	1.77e-04	3	176	2	CID000068481
Drug	AC1L1M7Y	CYP2A6 ABCC5 NLRP2 STAT3 SORT1	1.83e-04	68	176	5	CID000057056
Drug	wartmannin	MYH4 MYH6 ERBB4 MYH10 DNAJC13 MYH13 MYO1E RPS6KA2 UPF1 GDNF STAT3 ACTR1A MAPK15 ZFYVE9 AP1G1 GYS2 ROCK1	1.93e-04	811	176	17	CID000005691
Drug	Equithesin	MYH6 GDNF SORT1	2.36e-04	16	176	3	CID000170192
Drug	oleoylcarnitine	CPT1A GLUD1 GLUD2	2.36e-04	16	176	3	CID006441392
Drug	LY294002	MYH4 MYH6 ERBB4 MYH10 MYH13 RPS6KA2 NBN GDNF STAT3 ITPR1 SORT1 ACTR1A GSDME MAPK15 GYS2 ROCK1	2.39e-04	748	176	16	CID000003973
Disease	Primary familial dilated cardiomyopathy	MYH6 ABCC9 CRYAB SCN5A TAFAZZIN	7.81e-07	30	171	5	cv:C0340427
Disease	Primary dilated cardiomyopathy	MYH6 ABCC9 CRYAB SCN5A TAFAZZIN	1.50e-06	34	171	5	cv:C0007193
Disease	Familial dilated cardiomyopathy	MYH6 ABCC9 CRYAB SCN5A TAFAZZIN	5.58e-06	44	171	5	C0340427
Disease	Cardiomyopathy	MYH6 ABCC9 CRYAB SCN5A TAFAZZIN	7.77e-06	47	171	5	cv:C0878544
Disease	Cardiomyopathies	MYH6 ABCC9 STAT3 EPG5 CRYAB SCN5A TAFAZZIN	1.13e-05	130	171	7	C0878544
Disease	cholesteryl esters:total lipids ratio, high density lipoprotein cholesterol measurement	APOB CPT1A ADAM10 ABCA8 DNAH1 FDFT1 FADS2 MACF1 DOCK6	1.31e-05	243	171	9	EFO_0004612, EFO_0020944
Disease	coronary artery disease	CWF19L2 ERBB4 DNAJC13 PCNX3 CDK12 ARHGEF12 RNF213 APOB RSPH6A CERT1 DENND2B FCHO1 ABCA8 OPHN1 EPG5 OTUD7B DOCK5 PPP2R2A EDEM2 DOCK6	2.12e-05	1194	171	20	EFO_0001645
Disease	autosomal dominant hyaline body myopathy (implicated_via_orthology)	MYH4 MYH6 MYH13	2.23e-05	10	171	3	DOID:0111269 (implicated_via_orthology)
Disease	distal arthrogryposis type 2B3 (implicated_via_orthology)	MYH4 MYH6 MYH13	2.23e-05	10	171	3	DOID:0111602 (implicated_via_orthology)
Disease	distal arthrogryposis type 1 (implicated_via_orthology)	MYH4 MYH6 MYH13	2.23e-05	10	171	3	DOID:0111596 (implicated_via_orthology)
Disease	dilated cardiomyopathy 1S (implicated_via_orthology)	MYH4 MYH6 MYH13	2.23e-05	10	171	3	DOID:0110454 (implicated_via_orthology)
Disease	congenital myopathy 6 (implicated_via_orthology)	MYH4 MYH6 MYH13	2.23e-05	10	171	3	DOID:0080719 (implicated_via_orthology)
Disease	inclusion body myositis (implicated_via_orthology)	MYH4 MYH6 MYH13	2.23e-05	10	171	3	DOID:3429 (implicated_via_orthology)
Disease	distal arthrogryposis type 2A (implicated_via_orthology)	MYH4 MYH6 MYH13	2.23e-05	10	171	3	DOID:0111605 (implicated_via_orthology)
Disease	familial hypertrophic cardiomyopathy (implicated_via_orthology)	MYH4 MYH6 MYH13	2.23e-05	10	171	3	DOID:0080326 (implicated_via_orthology)
Disease	autosomal recessive polycystic kidney disease (biomarker_via_orthology)	CYP4A11 CYP4A22 SLC4A2	3.05e-05	11	171	3	DOID:0110861 (biomarker_via_orthology)
Disease	Phakomatosis cesioflammea	GNA11 GNAQ	3.34e-05	2	171	2	C3838883
Disease	Congenital hemangioma	GNA11 GNAQ	3.34e-05	2	171	2	C0235753
Disease	Port-wine stain with oculocutaneous melanosis	GNA11 GNAQ	3.34e-05	2	171	2	C1274879
Disease	cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement	APOB CPT1A ADAM10 ABCA8 DNAH1 FDFT1 FADS2 MACF1 DOCK6	3.58e-05	276	171	9	EFO_0004612, EFO_0020943
Disease	distal myopathy (implicated_via_orthology)	MYH4 MYH6 MYH13	4.05e-05	12	171	3	DOID:11720 (implicated_via_orthology)
Disease	1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) measurement	GREB1L FADS2 ROCK1	4.05e-05	12	171	3	EFO_0800453
Disease	myotonia congenita (implicated_via_orthology)	MYH4 MYH6 MYH13	4.05e-05	12	171	3	DOID:2106 (implicated_via_orthology)
Disease	triglyceride measurement, very low density lipoprotein cholesterol measurement	APOB ADAM10 CERT1 STAT3 DNAH1 FDFT1 FADS2 MACF1	5.18e-05	224	171	8	EFO_0004530, EFO_0008317
Disease	restrictive cardiomyopathy (implicated_via_orthology)	MYH4 MYH6 MYH13	5.24e-05	13	171	3	DOID:397 (implicated_via_orthology)
Disease	level of Phosphatidylcholine (16:1_18:1) in blood serum	GREB1L FADS2 ROCK1	5.24e-05	13	171	3	OBA_2045082
Disease	level of Phosphatidylethanolamine (18:1_18:1) in blood serum	MYO1E ADAM10 FADS2	6.64e-05	14	171	3	OBA_2045142
Disease	Malignant neoplasm of prostate	EPHB2 SERPINA3 CYP2A6 FOLH1 CDK12 NBN STAT3 SLC4A2 ITPR1 CRYAB PPP2R2A UCK2 SPINK5	6.70e-05	616	171	13	C0376358
Disease	distal arthrogryposis (implicated_via_orthology)	MYH4 MYH6 MYH13	8.27e-05	15	171	3	DOID:0050646 (implicated_via_orthology)
Disease	P wave duration	MYH6 SCN5A FADS2	8.27e-05	15	171	3	EFO_0005094
Disease	mean platelet volume	RALB MYO1E PCNX3 NDE1 FOLH1 CDK12 ABCC5 RSPH6A CERT1 DENND2B DOCK5 CTR9 GYS2 ANKRD11 FADS2 TAOK1 GNA11	9.68e-05	1020	171	17	EFO_0004584
Disease	Sick sinus syndrome	MYH6 SCN5A	9.98e-05	3	171	2	cv:C0037052
Disease	fascioliasis (biomarker_via_orthology)	GLUD1 GLUD2	9.98e-05	3	171	2	DOID:885 (biomarker_via_orthology)
Disease	Familial sick sinus syndrome	MYH6 SCN5A	9.98e-05	3	171	2	cv:C0340491
Disease	linoleic acid measurement	CYP2A6 SH3GL3 APOB CERT1 FDFT1 FADS2 DOCK6	1.11e-04	186	171	7	EFO_0006807
Disease	apolipoprotein A 1 measurement	CYP2A6 SPAST MAP1A APOB RSPH6A CPT1A ADAM10 GDNF ABCA8 PPARGC1B FADS2 MACF1 TMEM151A DOCK6 CNOT1	1.33e-04	848	171	15	EFO_0004614
Disease	apolipoprotein B measurement	MIX23 CYP2A6 DNAJC13 APOB CERT1 ABCA8 STAT3 SORT1 AP1G1 FADS2 TAOK1 PCMTD2 DOCK6	1.39e-04	663	171	13	EFO_0004615
Disease	very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio	APOB CPT1A ADAM10 CERT1 ABCA8 FDFT1 FADS2 MACF1	1.62e-04	264	171	8	EFO_0008317, EFO_0020944
Disease	level of Phosphatidylethanolamine (18:0_20:4) in blood serum	MYO1E ADAM10 FADS2	1.73e-04	19	171	3	OBA_2045140
Disease	apolipoprotein B to apolipoprotein A1 ratio	APOB CERT1 ABCA8 DOCK6	1.88e-04	49	171	4	EFO_0021897
Disease	free cholesterol to total lipids in small HDL percentage	APOB CPT1A ADAM10 FADS2	2.20e-04	51	171	4	EFO_0022285
Disease	Prostatic Neoplasms	SERPINA3 CYP2A6 FOLH1 CDK12 NBN STAT3 SLC4A2 ITPR1 CRYAB PPP2R2A UCK2 SPINK5	2.67e-04	616	171	12	C0033578
Disease	very low density lipoprotein cholesterol measurement, lipid measurement	CYP2A6 APOB ADAM10 CERT1 ABCA8 FDFT1 FADS2	3.10e-04	220	171	7	EFO_0004529, EFO_0008317
Disease	sick sinus syndrome (is_implicated_in)	MYH6 SCN5A	3.30e-04	5	171	2	DOID:13884 (is_implicated_in)
Disease	Malignant melanoma of iris	GNA11 GNAQ	3.30e-04	5	171	2	C0346373
Disease	Malignant melanoma of choroid	GNA11 GNAQ	3.30e-04	5	171	2	C0346388
Disease	phosphatidylcholine (16:0/22:5n3, 18:1/20:4) measurement	CPT1A FADS2	3.30e-04	5	171	2	EFO_0800467
Disease	Churg-Strauss syndrome (is_marker_for)	GDNF STAT3	3.30e-04	5	171	2	DOID:3049 (is_marker_for)
Disease	total cholesterol measurement, very low density lipoprotein cholesterol measurement	CYP2A6 MAP1A APOB ADAM10 CERT1 FDFT1 FADS2	3.46e-04	224	171	7	EFO_0004574, EFO_0008317
Disease	level of Phosphatidylethanolamine (16:0_18:2) in blood serum	MYO1E ADAM10 FADS2	3.54e-04	24	171	3	OBA_2045136
Disease	cholesteryl ester measurement, very low density lipoprotein cholesterol measurement	CYP2A6 APOB ADAM10 CERT1 ABCA8 FDFT1 FADS2	3.55e-04	225	171	7	EFO_0008317, EFO_0010351
Disease	colon cancer (is_marker_for)	MSH2 STAT3 ACTR1A NR5A2	3.87e-04	59	171	4	DOID:219 (is_marker_for)
Disease	very low density lipoprotein cholesterol measurement, phospholipid measurement	CYP2A6 APOB ADAM10 CERT1 ABCA8 FDFT1 FADS2	3.95e-04	229	171	7	EFO_0004639, EFO_0008317
Disease	triglyceride measurement, low density lipoprotein cholesterol measurement	CYP2A6 APOB ADAM10 STAT3 FDFT1 FADS2	4.28e-04	166	171	6	EFO_0004530, EFO_0004611
Disease	neutrophil count	CELF5 DNAJC13 RIPOR2 PDE6D MYO1E RC3H1 ARHGEF12 NIPSNAP2 ABCC5 DENND2B FCHO1 OTUD7B CENPP ACTR1A ANKRD11 FADS2 UCK2 DOCK6 SF3B5	4.39e-04	1382	171	19	EFO_0004833
Disease	Myxopapillary ependymoma	EPHB2 GDNF	4.93e-04	6	171	2	C0205769
Disease	Sick Sinus Syndrome	MYH6 SCN5A	4.93e-04	6	171	2	C0037052
Disease	childhood absence epilepsy (biomarker_via_orthology)	GLUD1 GLUD2	4.93e-04	6	171	2	DOID:1825 (biomarker_via_orthology)
Disease	Papillary ependymoma	EPHB2 GDNF	4.93e-04	6	171	2	C0334578
Disease	Lissencephaly	NDE1 MACF1	4.93e-04	6	171	2	C0266463
Disease	Anaplastic Ependymoma	EPHB2 GDNF	4.93e-04	6	171	2	C0280788
Disease	Cellular Ependymoma	EPHB2 GDNF	4.93e-04	6	171	2	C1384403
Disease	X-14939 measurement	CYP4A11 CYP4A22	4.93e-04	6	171	2	EFO_0800747
Disease	very low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	APOB CPT1A CERT1 ABCA8 FDFT1 FADS2 MACF1	5.10e-04	239	171	7	EFO_0008317, EFO_0020945
Disease	Hyalinosis, Segmental Glomerular	MYH10 MYO1E GNAQ	5.63e-04	28	171	3	C0086432
Disease	level of Phosphatidylethanolamine (18:0_18:2) in blood serum	MYO1E ADAM10 FADS2	5.63e-04	28	171	3	OBA_2045139
Disease	omega-3 polyunsaturated fatty acid measurement	APOB CPT1A FDFT1 FADS2 DOCK6	6.36e-04	118	171	5	EFO_0010119
Disease	beta-citrylglutamate measurement	NAALAD2 ABCC5	6.88e-04	7	171	2	EFO_0800060
Disease	lipid measurement, high density lipoprotein cholesterol measurement	MAP1A APOB ADAM10 ABCA8 FDFT1 FADS2 DOCK6 KNL1	7.14e-04	330	171	8	EFO_0004529, EFO_0004612
Disease	cardiomyopathy (implicated_via_orthology)	MYH4 MYH6 ERBB4 MYH13	7.82e-04	71	171	4	DOID:0050700 (implicated_via_orthology)
Disease	cortical thickness	CELF5 RIPOR2 CTTNBP2 RPS6KA2 SPTBN2 ARHGEF12 CUL9 ABCC9 ADAM10 LUZP1 PPP2R2A DUOX1 UBTF FADS2 MACF1 EPHA4	7.89e-04	1113	171	16	EFO_0004840
Disease	bitter non-alcoholic beverage consumption measurement	CYP2A6 ZNF365 PCMTD2	8.38e-04	32	171	3	EFO_0010093
Disease	alkaline phosphatase measurement	CYP2A6 DNAJC13 RIPOR2 MAP1A APOB CPT1A DENND2B ITPR1 ACTR1A FDFT1 ATF7IP EDEM2 FADS2 MACF1 CNOT1	8.74e-04	1015	171	15	EFO_0004533
Disease	docosahexaenoic acid measurement	APOB CPT1A FADS2 DOCK6 EPHA4	8.87e-04	127	171	5	EFO_0007761
Disease	Ependymoma	EPHB2 GDNF	9.14e-04	8	171	2	C0014474
Disease	Uveal melanoma	GNA11 GNAQ	9.14e-04	8	171	2	C0220633
Disease	low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	APOB CPT1A DNAH1 FDFT1 FADS2 MACF1	1.13e-03	200	171	6	EFO_0004611, EFO_0020945
Disease	myeloid white cell count	DNAJC13 PDE6D MYO1E RC3H1 VPS8 ARHGEF12 NIPSNAP2 ABCC5 BCL2A1 DENND2B FCHO1 CENPP ACTR1A FADS2	1.17e-03	937	171	14	EFO_0007988
Disease	Focal glomerulosclerosis	MYH10 MYO1E GNAQ	1.19e-03	36	171	3	C0017668
Disease	sphingomyelin measurement	TASP1 APOB UPF1 CERT1 ANKRD11 FADS2 DOCK6	1.23e-03	278	171	7	EFO_0010118
Disease	Developmental delay (disorder)	SPTBN2 UBTF TAOK1	1.29e-03	37	171	3	C0424605
Disease	total blood protein measurement	SERPINA3 DNAJC13 ARHGEF12 DNAH1 SP140L ARHGAP29 FADS2 MACF1 ROCK1	1.29e-03	449	171	9	EFO_0004536
Disease	triglycerides:total lipids ratio, high density lipoprotein cholesterol measurement	APOB CPT1A ABCA8 DNAH1 FDFT1 FADS2	1.32e-03	206	171	6	EFO_0004612, EFO_0020947
Disease	phosphatidylcholine measurement	NDE1 ZGRF1 APOB GREB1L FADS2 MACF1 DOCK6	1.39e-03	284	171	7	EFO_0010226
Disease	alpha wave measurement, electroencephalogram measurement	MSH2 DNAH1	1.46e-03	10	171	2	EFO_0004357, EFO_0006870
Disease	very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio	APOB CPT1A CERT1 ABCA8 FADS2 MACF1 DOCK6	1.60e-03	291	171	7	EFO_0008317, EFO_0020946
Disease	Inherited neuropathies	SPAST SPTBN2 ITPR1	1.61e-03	40	171	3	C0598589
Disease	free cholesterol measurement, very low density lipoprotein cholesterol measurement	CYP2A6 APOB ADAM10 CERT1 FDFT1 FADS2	1.64e-03	215	171	6	EFO_0008317, EFO_0008591
Disease	Cutaneous Melanoma	ERBB4 GNA11 GNAQ	1.73e-03	41	171	3	C0151779
Disease	Tachycardia, Ventricular	ABCC9 SCN5A	1.77e-03	11	171	2	C0042514
Disease	level of Sterol ester (27:1/20:5) in blood serum	CPT1A FADS2	1.77e-03	11	171	2	OBA_2045197
Disease	triglycerides:total lipids ratio, low density lipoprotein cholesterol measurement	APOB CPT1A ADAM10 FADS2 MACF1	1.86e-03	150	171	5	EFO_0004611, EFO_0020947
Disease	free cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement	APOB CPT1A ADAM10 CERT1 ABCA8 FADS2 DOCK6	2.01e-03	303	171	7	EFO_0004612, EFO_0020945
Disease	triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement	APOB CPT1A ADAM10 CERT1 ABCA8 MACF1	2.06e-03	225	171	6	EFO_0008317, EFO_0020947
Disease	autosomal dominant cerebellar ataxia (implicated_via_orthology)	ITPR1 PPP2R2A	2.12e-03	12	171	2	DOID:1441 (implicated_via_orthology)
Disease	PARKINSON DISEASE, LATE-ONSET	DNAJC13 GLUD2	2.12e-03	12	171	2	C3160718
Disease	arachidonoylcarnitine (C20:4) measurement	CPT1A FADS2	2.12e-03	12	171	2	EFO_0800544
Disease	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	STAT3 ATF7IP	2.12e-03	12	171	2	C0023485
Disease	lymphangioleiomyomatosis (is_marker_for)	CPT1A STAT3	2.12e-03	12	171	2	DOID:3319 (is_marker_for)
Disease	concentration of large LDL particles measurement	APOB CERT1 FADS2	2.13e-03	44	171	3	EFO_0022160

Protein segments in the cluster

Peptide	Gene	Start	Entry
KFKELAAEFSRMARD	ERBB4	966	Q15303
SMEKLQVEFDELFLR	EPG5	676	Q9HCE0
RIFTDREMKCLDANE	SLC4A2	1206	P04920
DTFSDDMAFKLDRRE	CDK12	81	Q9NYV4
KEADSMRADFSLLRN	CNTRL	2046	Q7Z7A1
TSFERMLSQKDLEIE	ANKRD11	1581	Q6UB99
DFIDSFLIRMQEEEK	CYP2A6	266	P11509
SERLKMNFDEDDREA	CRYBG3	2131	Q68DQ2
SEALEFMKRDLTEFT	BSDC1	26	Q9NW68
FRMFDRNTKRDITLE	PPP2R2A	366	P63151
MFVKEQLSLLDRFTE	SERPINA3	141	P01011
FNLRMKRDTSLFSDE	ADAM10	71	O14672
RMLLDYKAEVNARDD	ASB4	236	Q9Y574
MFAKATRNFLREVDA	GSDME	1	O60443
DRDDLTIMKRAIFST	GYS2	421	P54840
KRADMFSEEQLRTIF	ARHGEF4	316	Q9NR80
EEDFKRMTALAQDFA	CPT1A	196	P50416
LSDKDLRAEVDTFMF	CYP4A11	306	Q02928
TARTLFNQVMEKEFE	BCL2A1	66	Q16548
ETRFKQRMLELTDTN	ABCC9	1191	O60706
MIDSVKLRRDSAADF	CEP78	1	Q5JTW2
SKSIRRFLEVFMESQ	DENND2B	1066	P78524
AFRASFEDKLLMSDI	BMS1	1081	Q14692
SEFVSRAEERKDLFM	CENPP	151	Q6IPU0
MAETEERSLDNFFAK	CDV3	1	Q9UKY7
DFFMVLTDVDLRVKQ	CCDC80	711	Q76M96
VFDLIDTFQSRIKDM	CCDC80	736	Q76M96
RRDMFSDEQLKVIFG	ARHGEF9	136	O43307
EDFRQKRSMGLTLAE	ARHGEF12	481	Q9NZN5
DEDSSLMQLKEEFRT	RC3H1	261	Q5TC82
TRANVDKVFFDLMRE	RALB	161	P11234
ENKEFLEFRKARSDM	NIPSNAP2	146	O75323
NARIFLMDKDAEEIS	RASSF6	296	Q6ZTQ3
EFEDIMKRNRAISSS	CPSF7	336	Q8N684
SEMRLEKDRFSVNLD	CRYAB	66	P02511
RNHFSSTREEMEELK	OPHN1	236	O60890
DAQAAREFILKMFVD	GNAQ	301	P50148
STQDEETLALRDFMR	KIAA0513	86	O60268
ALRDLNTYTEKMREA	ZFYVE28	146	Q9HCC9
FERFLESTVETEKAM	ANKAR	1176	Q7Z5J8
DLDVSIKRRAMELSF	AP1G1	356	O43747
SLREKLAEMETFRDI	CERT1	156	Q9Y5P4
ISKDEFIRMLRSFIE	DUOX1	871	Q9NRD9
DFRSFIERDLIEQSM	OTUD7B	146	Q6GQQ9
EDFRALRKTAEDMNL	FADS2	111	O95864
RADFEQKMLDSALRF	FCHO1	186	O14526
RSLIDDKIREMQAFF	MMP27	56	Q9H306
KRMAENELSRSVNEF	DNAJC14	506	Q6Y2X3
DQLDKDINTFSMRVR	NOP56	176	O00567
LTQDFEEMKREERAL	MAP1A	531	P78559
RFSDDQLVSMSVREL	MAFA	226	Q8NHW3
EEARAKSEATIMFFL	MAGEE2	506	Q8TD90
SDDERRKAFAPIQEM	nan	261	A8MVJ9
MAETEALSKLREDFR	HTATIP2	1	Q9BUP3
EMDRIFANTESYLKR	NCBP1	191	Q09161
GMFRKDEELTSSQRD	MBOAT2	151	Q6ZWT7
SKDEIKERFAQTMEF	ITPR1	826	Q14643
RSNDKEDLCREFRSM	SPINK5	841	Q9NQ38
VFEFMDTDLNAVIRK	MAPK15	91	Q8TD08
RTEDFFKLERDMKIN	FOLH1	181	Q04609
SNEEIMRFSKLFEDE	LETM1	301	O95202
MRFSKLFEDELTLDN	LETM1	306	O95202
DKQRRDFLSEASIMG	EPHA4	661	P54764
FMESKEKDRQVLEDF	FDFT1	111	P37268
DLIFVTFQDSRMAKR	TMEM63C	341	Q9P1W3
LDNRMESFFLAETVK	EDEM2	421	Q9BV94
AALEEADKMFLRTRE	EID1	126	Q9Y6B2
EKQRRDFLSEASIMG	EPHB2	661	P29323
RMETIVFLDKEVFAS	PCMTD2	286	Q9NV79
DDASDEYKIIMLNRR	PCNX3	1706	Q9H6A9
MIADFLVERKTISFD	OR4K15	81	Q8NH41
RELNFSSTEQMEKFR	PDE6D	61	O43924
LDDMFVSKAAERERL	CWF19L2	636	Q2TBE0
IEKESRRMEEFTEFA	DNAH12	616	Q6ZR08
QIFMEKSTRDFSVDR	PEG10	101	Q86TG7
ASDMRFNEIFTEKEV	KDM4A	1021	O75164
SRVMDFFRRIDKDQD	MACF1	3171	O94854
ENVEELMDFFQASKR	EVC2	571	Q86UK5
DVDMVFASFIRKASD	PKM	236	P14618
ITRLFREKDDGMNFT	KNL1	296	Q8NG31
FDDVMDFIQATIKRL	GDNF	61	P39905
LMREIAQDFKTDLRF	H3-4	71	Q16695
MSDKRNVILFSVFDE	F8	586	P00451
DEMLERFKTEAQAFT	NLRP2	121	Q9NX02
RLDNEIQTKFEVFMR	GREB1L	751	Q9C091
AQMEEKLRDFTRAYE	MAST1	191	Q9Y2H9
EEMTQRLREFQESFK	MACF1	5011	Q9UPN3
TEVQLRFARDELDSM	BRIP1	411	Q9BX63
SVAVDRFKSLFLMEE	ABCC5	461	O15440
ERDIERSMKSLFFSS	ARHGAP29	916	Q52LW3
FDRMQSALKTFAVDE	UPF1	431	Q92900
EMLRNEDELEFAKRF	DAAM1	336	Q9Y4D1
FKLSDRDFLRSMENA	DNAH1	3256	Q9P2D7
KFRETLEDTRDRMYQ	APOB	2511	P04114
FRRLVSEVKMFTERD	CROCC	306	Q5TZA2
REAFFTIQRMEDKDE	IGSF1	731	Q8N6C5
LERQNLETFKDRMTE	CCDC150	801	Q8NCX0
DFIDSFLIRMQEEEK	CYP2A13	266	Q16696
FKTRQDIIDFLMETF	DOCK5	976	Q9H7D0
RLSDEDLFKFLADMR	DOCK6	466	Q96HP0
ADKSTRNEFRRFMEK	ANKZF1	576	Q9H8Y5
ISKIADSRDDLRMFD	CTTNBP2	1546	Q8WZ74
NELEKITRRFTMELA	GLUD1	196	P00367
LSDKDLRAEVDTFMF	CYP4A22	306	Q5TCH4
DAQAAREFILKMFVD	GNA11	301	P29992
FADTDKERTLRRMQQ	CELF5	211	Q8N6W0
DKMRFDLALAATEAR	CTR9	801	Q6PD62
FAIQKSDMDLRRTLF	ACTR1A	281	P61163
VLRDFFDSLNEAIMR	SLC1A6	291	P48664
REELKDTLESEMRAF	DNAJC13	781	O75165
DTLESEMRAFNIDRE	DNAJC13	786	O75165
FSRRKRSKSEDMDNV	ATF7IP	551	Q6VMQ6
RMAELEKLEEAFSRS	LUZP1	116	Q86V48
ESIRRFPSQEEFKDM	COQ5	286	Q5HYK3
REKSRGQRELEFSMA	CUL9	291	Q8IWT3
DRMFIQEEKTTLALD	BICRA	1176	Q9NZM4
AFNLVKSFMSEETRR	SEC14L4	201	Q9UDX3
EKVMADDEFTQDLFR	RYR1	3871	P21817
TDLRSDFSKFQEMIE	MSH2	441	P43246
ESLIDRDYMERDKEN	CUL4B	891	Q13620
NELEKITRRFTMELA	GLUD2	196	P49448
AMKAQFERDLQTRDE	MYH10	1571	P35580
KMATDFAENELDLFR	NSMCE1	96	Q8WV22
SDKRARSMDIDDFIR	DIMT1	286	Q9UNQ2
LADDIRERMSNVYSK	PTCHD3	471	Q3KNS1
RIFTEDRFAQDSEMK	PPEF2	86	O14830
LMVRFASLFDAKERT	NR1D2	446	Q14995
RSSIFFRELKVDDQM	NR5A2	361	O00482
EEENFRKTMLAKFAE	MNS1	371	Q8NEH6
DESFRIFLAMKQLVE	RSPH6A	321	Q9H0K4
EMEDRLSSESARQLF	UTP6	151	Q9NYH9
RFLFASVMADKDTTR	SORT1	311	Q99523
KDAERRDLTINSMFL	TRNT1	146	Q96Q11
TEYSRNLEKLAERFM	SRGAP1	61	Q7Z6B7
RKSSCVESFDDQRRM	TDRD6	1941	O60522
EESKELAERSMFNFL	SH3GL3	191	Q99963
KRPRMDIETNDTFSD	NBN	591	O60934
LNRFLEEERRTVSDM	PNMA3	106	Q9UL41
SDMSSRELKRRFEVF	PPARGC1B	911	Q86YN6
FTRESLAAIEKRMAE	SCN5A	16	Q14524
MNLEFSIRETTCRKD	SPP2	81	Q13103
QAREIEAFDSESMRL	TAOK1	871	Q7L7X3
REAEFQKMRRDLEES	MYH4	1171	Q9Y623
FEESRLIRMAEKAEF	VPS8	891	Q8N3P4
LKDVDFRESLMVFAD	TMEM151A	261	Q8N4L1
EMRNIRLSDFTESLK	SPAST	576	Q9UBP0
AEFQKMRRDLEEATL	MYH6	1171	P13533
RELITNKMFEDSEDS	SP140L	81	Q9H930
AENESKARVRFNLME	SF3B5	56	Q9BWJ5
ADRVMKQLEASFART	RIPOR2	831	Q9Y4F9
ERKTDRVILFSTQFM	ABCA8	661	O94911
STQFMDEADILADRK	ABCA8	671	O94911
QIFDKLQDMDERRAT	TRIP10	211	Q15642
KDFALDSEESRMRIA	CNOT1	1426	A5YKK6
MRKTEDECSFVSLRD	RNF213	2626	Q63HN8
IDFVRFKIRDMDSGT	UNC119	86	Q13432
SFEAHVREKFNRMVE	ZNF365	156	Q70YC5
YESTDDEDRQRMNKL	RNPC3	246	Q96LT9
EEFAEFQELLKVMRT	MIX23	11	Q4VC31
MLRDKFREFSRDTST	SPTBN2	1731	O15020
EMRKALTDFIQEEFQ	TAFAZZIN	231	Q16635
EARERKAKMTDFDRF	RPL14	96	P50914
ELFRNLMKSAFVVER	STAT3	311	P40763
EGLRDRDLITNKMFE	SP100	76	P23497
RRKMSFDIIDKSDVF	SUGP2	311	Q8IX01
DSLMIRFRTDDTINK	TLL2	981	Q9Y6L7
MKEDFERTKEELARS	MYH13	856	Q9UKX3
RDLFQMKLFVDTDAD	UCK2	146	Q9BZX2
MKLFVDTDADTRLSR	UCK2	151	Q9BZX2
SFEEAFQKALRMVDE	CAD	771	P27708
SFETRFEKMDNLLRD	ROCK1	6	Q13464
LEAMRTFCESAKQDR	UACA	446	Q9BZF9
EDFMVEFSETSLKAR	ZGRF1	1016	Q86YA3
EIEPENMREKFFRSL	ZBED9	216	Q6R2W3
IQRDFARDDMDFTEL	TMIGD3	156	P0DMS9
VSAMFIFSEEKRRQL	UBTF	411	P17480
EDQKRYERELSEMRA	UBTF	536	P17480
RKLELAERVDTDFMQ	TASP1	201	Q9H6P5
DSLRQALREMKDFTI	ZFYVE9	1236	O95405
QSTEEFENALKEMRF	ZW10	366	O43264
LFTRLSKEVMFTEED	RPS6KA2	146	Q15349
RTEDFFKLEREMGIN	NAALAD2	171	Q9Y3Q0
ARVFDFLVDSINKAM	MYO1E	361	Q12965
RMIDALFSFDSRIKV	MXRA5	2186	Q9NR99
ERSIFAMALQDRKAT	MYO7B	1501	Q6PIF6
RAKRATIMSLEDFEQ	NDE1	126	Q9NXR1